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Abstract
EVALUATION AND ADAPTATION OF LIVE-CELL INTERFEROMETRY FOR APPLICATIONS IN BASIC,
TRANSLATIONAL, AND CLINICAL RESEARCH
By Kevin Alexander Leslie, M.S.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University

Virginia Commonwealth University, 2018

Major Director: Dr. Jason Reed, Associate Professor, Department of Physics

Cell mass is an important indicator of cell health and status. A diverse set of techniques have
been developed to precisely measure the masses of single cells, with varying degrees of
technical complexity and throughput. Here, the development of a non-invasive, label-free optical
technique, termed Live-Cell Interferometry (LCI), is described. Several applications are
presented, including an evaluation of LCI’s utility for assessing drug response heterogeneity in
patient-derived melanoma lines and the measurement of CD3+ T cell kinetics during
hematopoietic stem cell transplantation. The characterization of mast cells during degranulation,
the measurement of viral reactivation kinetics in Kaposi’s Sarcoma, and drug response studies in
patient-derived xenograft models of triple-negative breast cancer are also discussed. Taken
together, data from these studies highlight LCI’s versatility as a tool for clinical, translational, and
basic research applications.
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Chapter 1
Cell Mass: A Versatile Biomarker
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1.0 Chapter Overview
This chapter provides a brief overview of cell mass, including its relevance as an indicator of cell
health, and techniques with which it can be measured. Cell mass is the common thread woven
through all of the experiments described in this dissertation, and the sections that follow aim to
orient the reader to this important intersection of single-cell biology and physics.
1.1 Introduction
Cell growth and proliferation are tightly regulated but incompletely understood processes.1,2 In
unicellular organisms like bacteria, they are generally governed by resource availability in the
extracellular environment.3 For multicellular organisms, comprised of varying tissue types and
proceeding through multiple stages of development, a more complex and coordinated system of
signaling is required to maintain homeostasis.4,5 This system, enabling individual cells to monitor
and change or maintain their size, relies on a combination of molecular gradients within the cells
themselves, mechanical signals from the extracellular environment, and paracrine and endocrine
signaling.6,7,8,9 Further, as cells can grow (accumulate mass) without dividing, it is important to
appreciate that these two processes, cell growth and cell division, can be differentially
regulated.1
A human’s survival and reproduction depends on the continuous and appropriate regulation of
cell growth and proliferation. Injuries to the skin must be rapidly repaired, immune cell
populations must expand in response to infection, egg cells must remain viable for decades, and
muscles must adapt to mechanical demands. Even cells that appear quiescent can be quite
dynamic, striking a delicate metabolic balancing act by exhibiting levels of biosynthesis identical
2

to growing or proliferating cells while simultaneously having higher levels of protein
degradation.10 However, when this system of regulated cell growth and division breaks down,
disease often results. Hearts can become enlarged, cancer can develop, and developmental
brain disorders can occur.11–13
The work described herein focuses on measuring the mass of a variety of human cells to
understand how their growth and division are impacted by different stimuli, including cytotoxic
drugs. In turn, this information could allow us to better understand basic biological processes,
predict drug efficacy, and even modulate therapeutic regimens for cancer patients.
1.2 Rationale
A red blood cell weighs just 27 picograms, on average, while an ovum can be 100,000 times
heavier, exceeding 3.5 micrograms.14 Neutrophils, important components of the immune
system, are renewed on an almost daily basis, while neurons of the cerebral cortex can last a
lifetime.15,16 This kind of dynamic range implies a corresponding heterogeneity in rates of mass
accumulation and division among human cell types.17 Logically, as common processes like
apoptosis (controlled cell death), growth, and division all encompass changes in cell size or
protein synthesis, cells should exhibit mass kinetic signatures that correspond with these
events.18 This should also hold true for cell type-specific functions like activation in T cells or
degranulation in mast cells.19–23 Taken further, significant dysregulation or disruption of any of
these processes should be detectable as a change in these kinetic signatures. However,
accurately characterizing baseline cell growth and, subsequently, detecting these kinetic
signatures requires the ability to non-invasively measure cell mass with picogram sensitivity.
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Within the last 15 years, significant progress has been made on this front, seeing the advent of
multiple measurement platforms capable of achieving single-cell resolution. These techniques
and their subsequent applications are discussed in the sections that follow.
1.3 Techniques for Measuring Cell Mass
Cellular biomass can be measured using a variety of techniques, including biochemical stains,
mass spectrometry, electron microscopy, various forms of interference microscopy, and
microbalances.24–50 However, most have seen limited use in clinical or research settings due to
their technical complexity, inadequate throughput, or limited precision.51–53 For the purposes of
this discussion, only techniques capable of measuring mass in living cells over time with
picogram precision will be considered; they will be categorized as either optical or non-optical
modalities.
1.3.1 Non-optical modalities
Non-optical modalities rely on indirect physical measurements to determine the mass of a cell.
The two most common are Suspended Microchannel Resonators (SMRs) and Pedestal Resonant
Sensors (PRSs). While these techniques can often be more precise than optical approaches, their
low throughput and inability to handle a variety of cell types (i.e. adherent and non-adherent,
clumps and single cells) tend to be limiting factors to their broad-scale adoption.
Suspended Microchannel Resonators
Suspended microchannel resonators derive the mass of a cell by measuring changes in the
vibrational frequencies of a silicon cantilever.54 Briefly, the cantilever contains a small channel
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through which liquid and particles or cells can flow. This cantilever is vibrated at multiple
frequencies and, using small piezoresistors embedded in the silicon surface or an external laser
doppler vibrometer, these vibrations are recorded.55 As a cell passes through the microchannel,
a detectable alteration of vibrational patterns is induced. These patterns can be used to derive
the buoyant mass of a cell. SMRs have been used successfully to measure a range of bacteria,
yeast, and mammalian cell types.56
The newest iteration of this technique involves arraying multiple SMRs in a serial fashion,
allowing the measurement of the same cell multiple times over the course of 15 minutes with a
precision of 50 femtograms; cells remain viable after passing through the channel. This setup has
been used to correlate drug-induced changes in single-cell growth rates in myeloma cells to drug
responses in several patients.57 However, SMRs are currently limited to analyzing 60-120 cells
per hour.58 In order to detect rare cells in a heterogeneous population or conduct screens on
multiple therapeutics simultaneously, a significant increase in throughput is required.
Pedestal Resonant Sensors (PRS)
Pedestal resonant sensors (PRS) operate similarly to SMRs. Briefly, the devices consist of an array
of small sensors (60 x 60 μm2) each suspended by a set of four nanoscale springs (80 μm x 4
μm).59,60 Single cells are deposited on, and subsequently attach to, these sensors. A laser doppler
vibrometer measures the resonant frequencies of these sensors, over time, in the presence of
the living cells. As cells change their mass, they detectably alter the resonant frequency of the
sensor to which they are attached. From these resonant frequency changes, cell mass can be
derived. Despite an ability to accurately measure cell mass over many hours, PRSs are not
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compatible with fluorescence microscopy, preventing correlative studies.56 Like SMRs, PRSs
suffer from low throughput (<100 cells measured simultaneously). In addition, adherent cells
often migrate off the sensor pedestals, complicating the process of tracking single cells for
multiple days.61
1.3.2 Optical modalities
Quantitative optical mass measurements of single living cells began in the 1950s48,62 and, thanks
to advances in both digital imaging technology and computing power, newer approaches have
increased in speed, precision, and practicality.26,27
In their most basic form, optical mass measurements of cells can be acquired using Michelsonstyle interferometry, which involves the extraction of information from the superimposition of
two light beams that have traveled separate paths after being split from a single illumination
source. The first beam passes through a target object (i.e. a cell), while the second (“reference”)
beam passes through a material that simulates the optical path of the first, without the target
object. Re-combination of these two beams yields an interference pattern from which the mass
of the target can be derived. Specifically, the interference pattern is a result of the differing
lengths of the optical paths (a product of the medium’s index of refraction and the geometric
length of the light’s path) between the two beams. The dense material in the target cell, through
which the first beam passes, increases the optical path length of the beam. When these path
length differences are calculated across the entire area of a target object, the optical density of
the object can be calculated. Optical density can be converted into dry mass by applying a
whole-cell-average dry mass ratio based on the average refractive indices of biological molecules
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(e.g., protein, DNA, RNA).46 Our group’s original live-cell interferometry platform utilized phaseshifting interferometry (PSI) which operates using the basic principles outlined above. However,
PSI also uses a piezoelectric transducer to rapidly introduce path length changes in one arm of
the Michelson-style setup during image collection, resulting in the generation of multiple
interferograms that enable the enhanced resolution of optical path differences.63
Variations on this technique have yielded an array of quantitative phase imaging (QPI)
microscopy platforms for the examination of biological specimens.56,64 A notable example is
digital holographic microscopy (DHM), wherein a laser light source is used to generate
holograms of living cells, enabling the reconstruction of three-dimensional images.65 The
technique, like all QPI-based modalities, requires no cell staining or labeling. It is also, uniquely,
afocal, as images can be digitally autofocused (within a range limited by the numerical aperture
of the microscope objective) after collection depending on the z-dimension layer of interest.
However, current implementations suffer from high noise as a result of multiple reflections and
laser speckling inherent to DHM.66 In addition, though DHM’s use of laser illumination poses
problems for long-term imaging of biological samples due to risks of phototoxicity, this can
generally be mitigated by using lower intensities or longer wavelengths.67
A low-noise alternative to DHM is quadriwave lateral shearing interferometry (QWLSI).26 In this
QPI variant, non-laser coherent light passes through living cells and is then sheared by a
diffraction grating into multiple replica wavefronts. These wavefronts combine to produce an
interference pattern that yields dry mass data on the target cells. Typically, this process is
condensed into a single camera unit, wherein the diffraction grating is fixed several millimeters
from the camera’s CCD sensor (on which the interference pattern is produced and recorded).
7

This modular camera approach enables the technique to be easily incorporated into existing
microscopy platforms and used in parallel with fluorescence techniques.
Recent applications of quantitative phase microscopy using other imaging platforms include
measurements of cell growth, cell death, membrane mechanics, individual organelles, and
preliminary imaging studies of mouse pluripotent stem cells (PSCs).60,68–71 Emerging translational
uses of the technique are highly promising, including its use in characterizing tissue
inflammation, wound healing, and circulating tumor cells.72–74
1.4 Live-Cell Interferometry (LCI)
Prior to the initiation of the work described herein, Reed et al. utilized early versions of an optical
single-cell mass measurement technique, termed live-cell interferometry (LCI), to investigate a
broad range of biological processes. Based on a Michelson-style phase-shifting interferometer,
early LCI platforms were precise but low-throughput, capable of measuring single cells with
picogram sensitivity and CV’s less than 1%, but slowed down by required focusing and image
collection times.
Initially, LCI was used to address questions in basic biology, such as the quantification of
cytoskeletal rearrangements in NIH/3T3 embryonic fibroblasts in response to mechanical
stimulation.75 Later studies focused on the appropriation of mass between daughter cells during
cell division, as well as the motility and distribution of mass in undifferentiated versus
differentiated human stem cell colonies.76,77
Applications eventually expanded to include the characterization of drug responses in a variety
of human cancer lines. Experiments using H929 multiple myeloma cells demonstrated the LCI’s
8

ability to determine sensitivity to Tunicamycin in several hundred individual cells by measuring
cell mass over time.78 This was followed by a similar set of experiments using Trastuzumab and
four breast cancer cell lines of varying HER2 statuses and clustering behaviors.25 Taken together,
these studies highlighted LCI’s ability to measure drug sensitivity in both adherent and nonadherent cell types, as well as single cells and/or cell clusters. This versatility remains one of LCI’s
fundamental advantages. However, at the time, the LCI’s throughput was a major limiting factor
in expanding to new translational research projects and improving its utility for existing
applications.
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Chapter 2
Technical Overview of Live-Cell Interferometry Systems
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2.0 Chapter Overview
This chapter provides hardware and performance descriptions of the original LCI system and its
high-speed successor, the HSLCI (High-Speed Live-Cell Interferometry) system. The sections that
follow provide technical context for the diverse range of applications described in later chapters.
2.1 Original State of the VCU LCI System
In 2012, the original VCU LCI system utilized phase-shifting interferometry63 and consisted of a
combination of two motorized linear translation stages, one small stepper motor, one flexure
stage, a CCD camera, a single LED illumination source, and a custom Michelson interferometric
imaging head. It was situated on a vibration isolation table and was not enclosed. A schematic
and image of the system are shown in Figure 1.
The core of this system was the interferometer head (Figure 2). Briefly, 660 nm collimated light
from a fiber-coupled LED source (Thorlabs, Inc.) enters the rightmost side of the head unit. This
light is split by a beam splitter into two beams: a reference beam and a sample beam. The
sample beam is directed towards the sample (containing beads or cells). The reference beam is
directed through a reference cell designed to mimic the optical path of the sample beam, minus
the actual sample. This reference cell is composed of two pieces of glass mounted in a small
aluminum block, separated by 700 μm steel spheres, and filled with distilled deionized water.
After passing through the reference cell, the reference beam encounters a mirror (whose
position is adjustable) and reflected back towards the original beam splitter. Both the reference
and sample beams are reflected (and subsequently recombined) towards the CCD camera after
re-encountering the beam splitter. The retardation of the sample beam relative to the reference
11

beam, caused by the higher index of refraction of the material encountered in the sample
objects, results in the generation of interference patterns in the light reaching the CCD camera.
In order for this technique to work, the interferometric head’s mirror must be positioned with
micrometer precision so that the lengths of the geometric paths traveled by both the sample
and reference beams are identical. Additionally, the sample’s tilt must be corrected so that the
objects being imaged are parallel to the imaging lens. Reference mirror positioning was
accomplished manually using an external rotary knob mounted to the side of the interferometer

Figure 1. Overview of original LCI
system hardware. Optical
components are arranged to form a
Michelson interferometer (the fixed
interferometer head contains the
reference arm and beam splitter).
Stepper motors and a flexure stage
are controlled using a custom
MATLAB interface and enable
sample navigation, focusing, and tilt
correction. Coherent light is
provided by an LED. A black and
white CCD camera collects images.
The entire system rests on a
vibration isolation table to minimize
noise.
head. Tilt correction was automatically performed using a stepper motor controlled by a custom
MATLAB script; a three-axis flexure stage (NanoMax-TS, Part# MAX301, Thorlabs, Inc.) enabled
rapid Z-direction adjustments for phase shifting. Sample navigation was performed using two
linear stepper motors (NRT100, Thorlabs, Inc.). Images were collected using a CCD camera
coupled to a Mitutoyo VMU and 40X objective lens.
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Samples were deposited onto 20 mm x 20 mm hand cut pieces of silicon wafer, submerged in
culture media, in one of four wells in a custom Teflon block. Custom “optical windows,”

Figure 2. Overview of original LCI system optics. Collimated light from a fiber-coupled LED
source enters the rightmost side of the head unit. This light is split by a beam splitter into
two beams: a reference beam (blue) and a sample beam (green). The sample beam is
directed towards the sample (containing beads or cells). The reference beam is directed
through a reference cell designed to mimic the optical path of the sample beam, minus the
actual sample. After passing through the reference cell, the reference beam encounters a
mirror (whose position is adjustable) and reflected back towards the original beam splitter.
Both the reference and sample beams are reflected (and subsequently recombined) towards
the CCD camera after re-encountering the beam splitter.

consisting of 28.6 mm stainless steel rings coupled to optical glass and supported by three 700
μm stainless steel spheres, were then placed on top of the silicon wafers.
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All sample navigation and image collection was performed and triggered using manual
micrometer manipulation combined with stepper motor movement and image acquisition
controlled through a simple MATLAB graphical user interface (GUI). Capturing a single 2 x 2 grid
of images required approximately 90 seconds.
After collection, images were processed using a combination of custom MATLAB scripts,
described previously by Reed et al. to unwrap the acquired phase images and calculate phase
shifts.78 Computed phase images were “flattened” by correcting for low-frequency background.
Single cells were segmented from the background of the flattened phase images using a spatialderivative edge detection kernel; their locations and optical volumes were recorded. Frame-toframe cell tracking was accomplished with a previously-described particle tracking algorithm.78
Single-cell growth tracks were generated for each object tracked and then plotted as optical
volume versus time. Performance of the system in this state was slow but robust, with data
revealing coefficients of variation (CV) less than 0.5% and picogram sensitivity.
2.2 Current state of the VCU LCI System
The current high-speed live-cell interferometry (HSLCI) platform consists of a custom-built
inverted optical microscope coupled to a quadriwave lateral shearing interferometric camera
(SID4BIO, Phasics, Inc.).26,79,80 The camera consists of a 1600 x 1200 pixel CCD camera (B1621,
Imprex, Inc.) fitted with a modified Shack-Hartman mask. It is self-referencing, simple to mount,
and capable of recording at 30 fps. The SID4BIO’s flexibility and image acquisition efficiency
ultimately precipitated its replacement of the LCI’s original interferometer head. Cells are
imaged in single, standard-footprint (128 mm x 85 mm), glass-bottomed, multi-well plates.
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Acquired images are analyzed in near real-time by a downstream PC (Dell Precision Tower 5810).
All of the platform’s hardware and software components are available commercially. A basic
schematic of the HSLCI system is provided in Figure 3.
Briefly, a multi-well plate holder coupled to three linear translation stages enables automated
sample movement in three dimensions during image acquisition. The scale of topographical
variation within and between multi-well plates necessitates a flexible and robust focusing
scheme (Supplementary Figure 1). Best focus is rapidly and consistently maintained during lateral
scanning using a custom-built automatic feedback loop consisting of a coaxial optical beam
deflection position sensor coupled to a one-dimensional piezo stack on which the microscope
objective is mounted. The sample is illuminated using a 660 nm LED light source that is
collimated and then strobed to coincide with the SID4BIO camera’s exposure, using a SID4BIOgenerated trigger, at a rate of 4 fps. After passing through the sample, the light is magnified by
an objective lens and directed to both the SID4BIO and a wide-field CCD camera (acA645-100,
Basler AG) utilized for correlative and fluorescent imaging (Figure 4). Either a 40X objective(Nikon
Plan Fluorite, NA 0.75), 20x objective (Nikon Neofluar, NA 0.5 or Nikon Plan Fluorite, NA 0.3) or a
10x objective (Nikon Plan Fluorite, NA 0.3) were used for the growth kinetics and population
studies described herein, depending on the desired size of the field of view. The entire HSLCI
platform is installed inside a standard cell culture incubator (Steri-Cult CO2 Incubator,
ThermoFisher) to maintain the environmental conditions necessary for cell viability.
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Figure 3. Overview of HSLCI system hardware. A 24-well plate containing samples for
imaging is secured in a custom stage. The sample is illuminated from above using collimated
light from an LED. Three stepper motors enable stage movement in X, Y, and Z directions for
sample navigation. The focusing module uses a feedback loop to maintain a fixed distance
between the objective and the plate bottom during imaging. The epifluorescence module
provides illumination for the excitation of fluorophores. The image collection module is
comprised of the Phasics QWLSI camera for the collection of interferograms and a color CCD
camera for the collection of brightfield and fluorescent images. Mirrors are represented by
solid green lines and dichroics are represented by double green lines.
2.3 Image Analysis
Briefly, raw interferograms acquired by the SID4BIO are converted to phase images using the
manufacturer’s software and then analyzed with our custom MATLAB (Mathworks, Inc.) scripts.
The phase calculation down-samples the raw interferogram image to 400 x 300 pixels, resulting in
effective pixel sizes between 1.3 μm and 2.5 μm, depending on the objective.
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The intensity signal across the phase image matrix is deconvolved in the Fourier domain around
the spatial period of the diffraction grating to generate an unwrapped phase image. This a phase
gradient that is then numerically integrated to derive the optical path difference. The optical path
difference (OPD) is defined as a function of the spatial position in the wavefront.
ℎ

𝑂𝑃𝐷(𝑥, 𝑦) = ∫ [𝑛(𝑥, 𝑦) − 𝑛𝑚𝑒𝑑𝑖𝑢𝑚 ]𝑑𝑧
0

Here, n is the refractive index of the specimen and nmedium is the refractive index of the medium.

Figure 4. Schematic of HSLCI optical hardware and accompanying ray diagrams. Samples are
imaged in standard-footprint multi-well plates. Phase images are collected by an off-axis
QWLSI camera. Best focus is maintained using a feedback loop to measure the distance (f)
between the multi-well plate’s bottom and the microscope objective. Changes in f are
detected using an infrared laser and quadrant photo diode (QPD). A piezo actuator
coupled to the objective compensates for any detected change by adjusting the position
of the objective in the z direction. (Adapted from Guest, D. 2017)

The difference is integrated over the total thickness h in the direction of propagation. As the
resulting value is a combination of OPD from the sample and the OPD from the imaging system, a
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reference image is captured prior to imaging the sample; we eliminate any contribution from the
imaging system by subtracting the reference image. The OPD is then used to derive the optical
volume difference OVD, wherein the OPD is integrated over the total imaging surface (S). Hence,

𝑂𝑉𝐷 = ∬ 𝑂𝑃𝐷(𝑥, 𝑦)𝑑𝑥𝑑𝑦
𝑆

This value is directly proportional to the dry mass of the cell (referred to herein as “biomass”) by
a constant known as the specific refractive increment α. The specific refractive increment is the
rate of change in the refractive index n of a specific specimen.

∬ 𝑂𝑃𝐷(𝑥, 𝑦)𝑑𝑥𝑑𝑦 = 𝛼 ∙ 𝑚
𝑆

This can be rearranged as

𝑚=

1
𝑆 ∙ 𝑂𝑃𝐷
𝛼

to find the mass (m), where S is the surface area of the specimen in microns. For the experiments
1

described herein, 𝛼 is equal to 5.56

𝑝𝑔
𝑢𝑚3

.48

Computed phase images are “flattened” by correcting for low-frequency background noise
inherent to the shearing interferometry method. Single cells are segmented from the background
of the flattened phase images using a spatial-derivative edge detection kernel; their locations and
optical volumes are recorded. An example of step-wise images from this process is provided in
Figure 5.
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Frame-to-frame cell tracking is accomplished with a previously-described particle tracking
algorithm.78 Single-cell growth tracks are quality filtered using an upper cutoff of +/-15%
uncertainty (SD of residuals) in the calculated growth rate, as determined by linear fitting the dry
mass versus time data.
2.4 HSLCI Platform Performance Metrics
In its current configuration, the HSLCI system can, at a minimum, collect and process 960 images
from as many unique locations in a multi-well plate every 10 minutes, yielding biomass data on
at least 103– 104 individual cells. Due to the mechanical and environmental stability of the HSLCI
system, we have been able to track single cells and cell clusters for up to 10 days, with no time
limit yet found. The HSLCI’s stages enable lateral scanning at a maximum velocity of 2mm per
second, while the SID4BIO camera is capable of capturing data at rates up to 30 fps. For a 24well plate, even at a capture rate of 4 fps, this translates to only 2.5 minutes needed to acquire
240 unique images (40 images/well) in a single six-well column. After acquisition, deriving a
phase image from a single raw interferogram typically requires 500 ms, while the remainder of
post-processing (flattening, cell segmentation, and cell tracking) typically requires 500-1,000 ms,
on a single Intel Core i7 processor. Compared to our prior implementations, our current pipeline
conducts image processing as soon as images are acquired and parallelizes these steps across
eight or more processors on a single high-performance PC, resulting in near real-time processing.
An overview of the HSLCI imaging and data analysis pipeline is provided in Figure 6.
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Figure 5. Example of HSLCI image processing pipeline steps. Images shown are of the same location
at three different time points. Brightfield and fluorescent images were collected with a Basler color
CCD camera and did not undergo processing after acquisition. Interferograms were collected by a
Phasics QWLSI camera and were subsequently converted into unwrapped phase images, flattened,
and segmented to yield mass data for single cells.
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Figure 6. HSLCI performance overview. Prior to imaging, cells and media (including drug or
vehicle) are dispensed into standard-footprint, glass-bottomed multi-well plates. During
imaging, the sample plate is translated along each row of wells, collecting 30 images per well
on each pass. Following collection, phase images are automatically analyzed in a custom
pipeline that includes background flattening, cell detection and segmentation, and biomass
calculation. Individual cells are tracked between images based on their position, and biomass
versus time plots are generated.
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Chapter 3
Quantifying Melanoma Drug Resistance and Heterogeneity
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3.0 Chapter Overview
This chapter details the deployment of HSLCI during a multi-year study on drug resistance and
heterogeneity in patient-derived melanoma cell lines. This project was planned and executed in
close collaboration with the Dr. Michael Teitell’s laboratory at the University of California – Los
Angeles (UCLA). The text and figures that follow have been adapted (reproduced with permission
of The American Chemical Society and co-authors) from a publication of the study’s results, cofirst authored by K. Leslie and D. Huang, in the journal Analytical Chemistry.81
3.1 Introduction
An estimated 91,270 new cases of cutaneous melanoma with 9,320 deaths will occur for the
United States in 2018.82 Despite comprising less than 2% of skin cancer diagnoses, melanoma is
responsible for 75% of skin cancer deaths.83 Genetic landscape studies show inter-patient, intrapatient, and intra-tumor heterogeneity. About 50% of melanomas harbor an activating mutation
in the BRAF gene, whereas 10-25% of cases show an activating RAS mutation, 12-18% are
mutant in NF1, and 7-28% of tumors show mutations in genes that include AKT and PTEN. Most
of these mutations increase MAPK pathway signaling activity, which regulates cell proliferation,
differentiation, and survival.84–87 Targeted therapies, most notably against BRAF V600E and
V600K activating mutations, have improved progression-free survival for many melanoma
patients.88 However, therapy resistance emerges in most cases of BRAF or MEK inhibitor
monotherapy, often from preexisting or acquired mutations that reactivate the MAPK pathway
downstream of the drug-targeted site.89 Current BRAF and MEK inhibitor combination therapies
aim to reduce the frequency of emergent resistance.90,91 Drug selection guidance comes from
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clinical tumor staging, mutation screening, patient health, and prognostic factors such as lactate
dehydrogenase levels.92 Despite multifactorial guidance, resistance eventually develops even for
up to 80% of patients receiving combination therapy.88 Genetic heterogeneity underlying
mechanisms of preexisting and acquired resistance makes mutation screening incompletely
predictive of drug susceptibility, both prior to the start of therapy and after the development of
resistance, and increases the difficulty of selecting efficacious frontline and second-line
therapies.93–95
Current efforts in repeat tumor assessment focus on noninvasive liquid biopsy methodologies
such as the detection and analysis of circulating exosomes, microRNAs, circulating tumor DNA,
circulating tumor cells, and proteomic profiling of serum proteins by mass spectrometry.96,97
While samples from the circulation provide easily accessible materials that may be more
representative of a patient’s tumor heterogeneity than single-site tumor biopsies, there are
presently no reliable molecular biomarkers from circulation sampling to guide targeted
melanoma therapy or improve outcome predictions.98–100 Other limitations include a lack of
standardization, low sample yields, and the high cost of post-isolation analyses, which makes
many circulation-sampling methods impractical for broad-scale clinical implementations in their
present state.101,102
An alternative to circulating biomarkers is the in vitro measurement of drug responses in excised
tumor cells using chemosensitivity assays, such as ATP quantification or assessments of cell
metabolic activity.103–106 Advocated by major cancer centers and international research
organizations, such as the American Society of Clinical Oncology (ASCO), chemosensitivity assays
have seen minimal adoption in melanoma treatment. This is due to long, three-to-seven day
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turnaround times that increase the likelihood of artifacts, a lack of supporting large-scale
clinical trials, and interference from heterogeneous co-harvested tumor elements (such as
stromal fibroblasts) that often overrun cultures and may result in false or misleading data. 107–
111

Further, the most popular cell death assays using ATP or MTT measurements are bulk

methods, which is a significant limitation for typically-heterogeneous cancers, especially given
that growth arrest and senescence (rather than sudden cell death) are common drug responses
and resistance mechanisms.108,111–114 By contrast, acute cell killing assays can provide data at a
snapshot in time using fresh tissue, but have not proven sufficiently informative as stand-alone
assays.115–119
High-content screening systems based on confocal microscopy, such as the commerciallyavailable GE In Cell Analyzer (General Electric, Inc., Boston, MA)and Yokogawa CV8000
(Yokogawa Electric Corporation, Tokyo, Japan) platforms, were introduced as a versatile
solution to many of these problems through their combined use of automation, environmental
controls, and compatibility with a variety of assays. Unfortunately, these systems still require
that cells be labeled for chemosensitivity and cytotoxicity testing. A superior, high -throughput,
reproducible, standardized, and inexpensive approach to determine drug sensitivity before
(and periodically during) therapy is, therefore, desirable.
A variety of in vitro and ex vivo methodologies have emerged to address the shortcomings of
these traditional cell viability assays in the context of personalized cancer care (Figure 7).
Specifically, newer strategies have focused on reductions in turnaround time and sample
quantity via microfluidics, a more accurate simulation of the tumor microenvironment, and
novel non-genetic biomarkers of drug sensitivity. 120–122 Despite progress in these areas, the
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field has not yet achieved the required combination of accuracy, throughput and single-cell
sensitivity needed for predictive assays to guide cancer treatment selection
We have previously shown that optical interferometric microscopy provides an exciting potential
solution by profiling drug-induced growth arrest in living single cells or cell clumps via changes in
biomass over time with picogram sensitivity.25,78 However, this proof-of-principle work consisted
of single agent, small-scale studies of limited duration. The key remaining engineering challenge
is to create a reliable platform for multi-agent, multi-concentration parallel screens without
sacrificing measurement accuracy or assay acceleration. Meeting this challenge

Figure 7. Overview of cell viability assays used for drug sensitivity screening. The majority
(93%) of viability assays require the use of one or more labeling molecules to assess cell
growth or viability. Of the label-free methodologies, only quantitative phase imaging has
demonstrated throughput comparable to label-based techniques while maintaining singlecell resolution.
requires, at a minimum, an order of magnitude increase in the number of different conditions
tested within a single experiment, and a corresponding increase in the number of individual cells
analyzed per hour. This is a sizable hurdle, for a variety of methodological reasons, but is
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absolutely required to enable practical, rapid response profiling of patterns of drug resistance,
intra-tumor heterogeneity and for ultimately developing a reproducible therapy selection
method.
To reach this goal, we created and deployed the HSLCI (Figure 8). HSLCI’s dynamic focus
stabilization enables continuous image collection over the entire sample area without pause, and
stage-top or whole microscope enclosures provide long-term environment stability for imaging
under physiology-approximating conditions (37 oC, 5% CO2). The HSLCI captures images from
standard format, glass bottom multi-well cell culture plates and each well can contain a different
cell type exposed to a unique drug dose or combination. The experiments described here
utilized 4-well and 24-well glass bottom plates, although well counts of up to 96 are possible
depending on the experimental conditions, including cell concentration, population sampling
depth, required temporal resolution, and other parameters. This present work describes a twocenter study using HSLCI to quantify biomass kinetics for three isogenic sensitive/resistant pairs
of patient-derived, V600EBRAF mutant melanoma cell lines in response to the BRAF inhibitor
(BRAFi), Vemurafenib, and a battery of FDA-approved kinase inhibitors. We show that HSLCIquantified biomass kinetic signatures during 24 hours of drug exposure discriminates between
drug-sensitive and drug-resistant tumor subpopulations. HSLCI data are reproducible between
study sites and consistent with longer multi-day growth inhibition assays.
Of particular practical importance for any future clinical laboratory use is HSLCI’s compatibility
with pre-sterilized, disposable, and standard format multi-well sample plates. This enables
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Figure 8. Schematic of HSLCI multi-well biomass accumulation assay. A) The HSLCI system is
configured with (i) a wide-field phase-detection camera, (ii) fiber-coupled light-emitting
diode (LED) illumination source, and (iii) and fluorescence imaging capability (camera, filters,
and illuminator). Motorized stages (iv) control x–y motion of the sample above the
microscope objective, while focus is automatically adjusted continuously by a piezo actuator
coupled to the objective [10× Nikon Plan Fluorite, numerical aperture (NA) 0.3]. B) Prior to
imaging, cells and medium, including drug or vehicle, are dispensed into standard-format,
glass-bottom mult-iwell plates. C) During imaging, the sample plate is translated along each
row of wells, collecting 30 images/well on each pass. Typical imaging time is 2 min/row of six
wells. D) Following collection, phase images are automatically analyzed in a custom pipeline
that includes background flattening, cell detection and segmentation, and biomass
calculation. E) Individual cells are observed between images on the basis of their position,
and biomass versus time plots are generated. Shown is a typical normalized mass vs time
plot for single Vemurafenib-sensitive (red) and Vemurafenib-resistant (blue) cells.

efficient screening of multiple drugs and drug combinations in a single assay, simplifies sample
handling, and avoids the need to sterilize and wash dedicated microfluidic components between
runs.
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3.2 Methods
Cell Lines
M229P, M229R5, M238P, M238R1, M249P and M249R4 cell lines were grown in DMEM high
glucose with 10% heat-inactivated FBS (Omega Scientific) and 2mM glutamine in a 37 ⁰C,
humidified, 5% CO2 incubator. M229R5, M238R1 and M249R4 cells were exposed to 1 µM
Vemurafenib every 2 – 3 days. Cell counting from 6-well plates with controls and a range of
Vemurafenib concentrations was performed for five days following overnight seeding.
Population Kinetic Response Experiments
Cells were synchronized by growing to confluence in 75mL tissue culture flasks and collected
using a “shake-off” technique that involved repeated tapping of the flasks against the palm to
loosen partially-adherent (i.e. dividing) cells. Cells were plated at 1 x 105 cells/ml in 25 mm
dishes and incubated overnight. Prior to imaging, samples were equilibrated thermally for one
hour on the microscope stage, then imaged for three hours, after which either 0.1% DMSO
vehicle control or 5 μM Vemurafenib was administered and dishes imaged for another 25 – 30
hours.
Vemurafenib dose response experiments. Cells were first synchronized by shake-off, and each of
the six melanoma cell lines seeded into four wells each of a 24-well glass bottom plate at 1 x 105
cells/ml, and incubated overnight. Each line was dosed with 0.1% DMSO carrier control, or 1
μM, 5 µM, or 10 µM Vemurafenib. Cells were incubated for 24 hours, then the entire plate was
imaged on the HSLCI for 10 hours.
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Fluorescence Mixing Experiments
1.25 x 104 M249P and M249R4-GFP cells were added together in a total volume of 1mL tissue
culture media. 0.7 mL of the mixture was dispensed into each well of an Ibidi 4-well Ph+ µ-slide.
Cells settled over 6 hours after which 5µM Vemurafenib was added to each well. Ibidi oil sealed
the liquid opening of each well before the plate was placed onto the LCI stage. All wells were
imaged continuously for 48 hours. Fluorescence images were taken using a Hamamatsu EM CCD
camera (C9100-02 EMCCD) serially after every 5 phase imaging loops were completed. Green
fluorescence was captured using a 38 HE Green Fluorescent filter set (Zeiss) with an excitation
wavelength of 450-490 nm, a beam splitter wavelength of 496nm and an emission wavelength of
500-550 nm. Fluorescence excitation was provided by an X-Cite® 120Q wide-field fluorescence
microscope excitation light source (Excelitas).
Kinase Inhibitor Panel Assay
M249R4 cells were plated in a 24-well optical glass-bottomed plate (Cat.# P24-0-N, Cellvis) at 1 x
104 cells/ml (total of 1 mL in each of 24 wells) in media (DMEM, 10% Fetal Bovine Serum, 2 mM
L-Glutamine) containing 1uM Vemurafenib. Plated cells were allowed to adhere overnight at 37
⁰C, 5% CO2. All cells were washed with 1x phosphate-buffered saline, pH 7.4, and provided with
fresh media. Immediately following washing and feeding, cells were dosed with inhibitors at
dose-escalating concentrations and incubated under standard cell culture conditions for 24
hours. After incubation, cells were imaged for 10 hours using the HSCLI system.
3.3 Results
Isogenic BRAFi-Sensitive and –Resistant Melanoma Cell Lines
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We evaluated three patient-derived V600EBRAF melanoma cell lines, M229P, M238P, and
M249P, which are sensitive to the BRAFi, Vemurafenib (IC50 < 1 μM), and their isogenic, BRAFiresistant sub-lines, M229R5, M238R1, and M249R4, created by Vemurafenib co-incubation over
time (Supplementary Table 1). M229R5 and M238R1 developed BRAFi resistance via epigenomic
reprogramming, which is thought to occur in regressing or residual melanoma tumors from
patients treated with MAPK inhibitor (MAPKi) therapy. This non-genomic evolution results in a
MAPK-redundant form of resistance.33 On the other hand, M249R4 acquired a Q61KNRAS
mutation in addition to the V600EBRAF mutation. This concurrent BRAF/NRAS mutant
configuration results in MAPK hyper-activation and a MAPK-addicted form of resistance, which is
frequently detected during disease progression or with clinical relapses.34-36 Thus, these pairs
of cell lines represent pre- and post-treatment models of differential drug-sensitivity states that
are clinically relevant and, therefore, we used these lines to evaluate HSLCI performance in
biomass profiling.
Biomass Kinetic Responses to Vemurafenib Exposure
Our previous work in breast cancer and multiple myeloma indicated that changes in the
population median growth rates between sensitive and resistant cell lines is detectable with
confidence within a few hours of drug exposure.25,78 We also showed that the distribution of
growth rates within a population is roughly Gaussian, in both treated and control samples.
There is no existing data for the rate of biomass change of BRAFi-sensitive or -resistant
melanoma cells that grow as adherent single-cells or clumps. Therefore, we measured the
kinetics of Vemurafenib response in the three paired, molecularly characterized melanoma lines
using HSLCI, to establish rates and distributions of biomass change with or without drug
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exposure. First, we performed a standard multi-day dose-escalation cell-counting assay to
confirm sensitivity for the three parent and matched resistant lines at 1.0 µM to 10.0 µM
Vemurafenib exposure (Supplementary Figure 2). As anticipated, the parental lines slowed and
the matched resistant lines continued replicating with drug exposure. We next used 5µM
Vemurafenib as the mid-point drug dose to measure the median population growth rate and cell
mass by HSLCI for the six cell lines in the first 25 hours of drug exposure, in order to quantify the
average population kinetic response (Figure 9-A). Under these conditions, drug sensitivity of the
M249P population was detectable as early as six hours, while sensitivity of the M238P and
M229P populations was detected at approximately 15 hours. Significant growth rate reduction
occurred in all three parental lines by 20 hours. We observed significant natural variation in the
growth rates of individual cells within each population, a result consistent with previous LCI
studies. The distribution of single cell hourly growth rates was typically symmetrical about the
mean, with variation of roughly +/- 1% (SD) above and below the population mean. For example,
plotting the M249P growth rate distribution obtained by HSLCI for each hour showed no change
in the population median growth rate nor in the cellular growth rate distribution over the course
of the 25 hour experiment. (Supplementary Figure 3-A) In contrast, under the same conditions 5
µM Vemurafenib exposure showed population growth rate heterogeneity and a decline below
zero growth rate by about 15 hours for >50% of cells (Supplementary Figure 3-B), indicative of
the relative sensitivity of this line to the BRAF inhibitor. Similar temporal single cell growth rate
distributions were seen in the other five cell lines, with kinetics proportional to the line’s overall
median sensitivity. These results reproduced at both experimental sites with independently
assembled HSLCI platforms.
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Figure 9. Biomass accumulation response to Vemurafenib treatment. A) Normalized
population median biomass versus time plots of each melanoma line exposed to either 5
μM Vemurafenib (red trace) or 0.1% dimethyl sulfoxide (DMSO, blue trace). Cells were
synchronized prior to plating in glass-bottom dishes. Each sample was imaged for 3 h, after
which either 0.1% DMSO (vehicle control) or 5 μM Vemurafenib (treatment) was
administered. After dosing, plates were imaged for 20–25 h by HSLCI under standard cellculture conditions. Typical time between repeated measurements of the same location was
10–15 min. Each graph contains pooled data from four replicates. Error bars are ± standard
error of measurement (SEM). B) All six synchronized cell lines were plated into a single 24well glass-bottom plate and dosed with either 0.1% DMSO or 1, 5, or 10 μM Vemurafenib.
After 24 h of incubation, the plate was imaged continuously for 10 h by HSLCI. Hourly
growth rates were automatically calculated for individual cells in each sample by linear fit to
the biomass versus time data. Data are from a single representative experiment (n = 3). Boxplot notches are 95% confidence intervals for the indicated medians. Each dot overlaid on a
box plot represents the hourly growth rate of an individual cell. C) Corresponding receiver
operator characteristic (ROC) curves for data shown in panel b.

By comparing the median cell mass of the Vemurafenib-resistant melanoma lines to the mass of
their isogeneic, drug sensitive parent lines, we found no consistent correlation between mass
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and resistance (Figure 10). This observation stands in contrast to a recent report of cell massdrug resistance correlation in a mouse AML model, as measured by microfluidic devices.123
However, that study did not compare isogenic, paired sensitive and resistant tumor lines, and it
remains to be determined whether or not mass itself is a useful metric of drug sensitivity.

Figure 10. Comparing relative mass between Vemurafenib-sensitive and -resistant isogenic
lines. Boxplots showing distribution of single cell masses measured for each cell line. Boxplot
notches are indicative of the 95% confidence intervals for the medians.

The mid-point kinetic response data suggested that Vemurafenib sensitivity, or lack thereof,
would be distinguishable for all lines in a drug-escalation assay, as would be expected for cell
counting, by measuring changes in sample growth rates after 24 hours of drug exposure. To test
this hypothesis, and to examine the HSLCI methodology for multi-dose and multi-agent
screening, we collected short-term, 10-hour growth rate measurements of all three cell line pairs
in parallel, at escalating Vemurafenib doses, using a 24-well format. All six melanoma cell lines
were dosed with 0.1% DMSO, or 1 μM, 5 uM, or 10 μM Vemurafenib. The parental lines
(M229P, M238P, and M249P) showed a clear pattern of increasing growth inhibition at
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escalating drug concentrations, whereas the resistant lines (M229R5, M238R1, and M249R4)
showed no growth inhibition over the drug dosing range compared to a vehicle DMSO control,
consistent with cell counting assays (Figure 9-B).
Heterogeneity Quantification
We used Receiver Operator Characteristic (ROC) analysis to determine the ability to distinguish
individual resistant cells from sensitive cells, in an in silico mixture, by changes in their individual
growth rates during exposure to Vemurafenib. (Figure 9-C) This analysis indicated that cells from
both M229P and M238P lines were distinguishable from their resistant derivative counterparts
at Vemurafenib doses of 5uM (area under the curve (AUC), 0.60 and 0.85, respectively) and
10uM (AUC, 0.78 and 0.75, respectively). The M249P cells were the most sensitive to drug and
easily distinguishable based on changes in growth rate, with AUC greater than 0.90 at
Vemurafenib doses of 1uM and above (Figure 11).
We then deployed HSLCI to quantify the changes in growth rates of an actual mixed population
of GFP-labeled M249R4 Vemurafenib-resistant (M249R4-GFP) and unlabeled M249P
Vemurafenib-sensitive cells during drug exposure. Importantly, stable GFP-expression in the
M249R4 line did not significantly alter the growth rate distribution obtained by LCI for each hour
of 5µM Vemurafenib exposure compared with unlabeled M249R4 cells (Supplementary Figure 3C). Sensitive M249P and resistant M249R4-GFP cells grown together at a 1:1 ratio with 5uM
Vemurafenib were imaged over 48 hours (Figure 12 A-C).
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Figure 11. Vemurafenib (5 uM) sensitivity as determined by plotting pre- and post-treatment
growth rates for Vemurafenib-sensitive (M249P) and Vemurafenib-resistant (M249R4) cell
lines. a) Plot of pre- and post-treatment hourly growth rates. Blue data points represent
individual cell growth rates from the drug-sensitive cell line; red indicates data points from
the drug-resistant line. b) ROC curve demonstrating efficacy of using calculated final growth
rates to determine Vemurafenib sensitivity
In mixed culture, individual resistant cells were discriminated from sensitive cells based on
differences in growth rates (Figure 12-D) and because the M249R4 cells were GFP marked, they
were easily identified relative to the unmarked M249P cells during the assay. Reproducibly, the
population growth rate of the M249R4 cells exceeded the population growth rate of the M249P
cells, as expected, but each marked and unmarked population also showed outlier cells. A small
percentage of M249R4-GFP cells showed zero to slightly negative growth rates, whereas a small
percentage of M249P cells showed net-positive growth rates, revealing unanticipated
Vemurafenib sensitive or resistant outliers within each bulk population. As predicted from the in
silico analysis, ROC analysis confirmed a high level of discrimination between sensitive and
resistant melanoma cells (AUC 0.88), even when sensitive and resistant cells were combined in
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Figure 12. Detecting resistant cells in a mixed population. A) Optical thickness (LCI, left) and
in-register fluorescence images (FL, right) of M249R4-GFP vemurafenib-resistant cells. B)
LCI and fluorescence images of M249P vemurafenib-sensitive cells. C) LCI and fluorescence
images of a 1:1 mixture of M249P (red arrows, unlabeled) and M249R4 (labeled) cells. D)
Plot of biomass versus growth rate of a 1:1 M249P (blue)/M249R4-GFP (red) cell mixture
exposed to 5 μM vemurafenib for 48 h. Cell identities are marked by fluorescence signals.
E) ROC curve classifying single sensitive versus resistant cells by their growth rates during
exposure to 5 μM vemurafenib. The blue line is calculated from M229P and M249R4 cells
imaged in separate wells, whereas the red line is calculated from a 1:1 cell mixture in the
same wells (representative data are shown in panel d). Data shown are from a single
representative experiment (n = 3–5).

the same sample wells (Figure 12-E). Similar trends were seen in 10:1 sensitive: resistant
mixtures as well (Supplementary Figure 4).
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MEK Inhibitors with Vemurafenib-Resistant Melanoma
We performed rapid HSLCI dose response assays in triplicate using a panel of three FDAapproved and two investigational kinase inhibitors tested in clinical trials for treating metastatic
melanoma, to simulate selection of salvage therapy for patients who develop resistance to front
line Vemurafenib. One inhibitor in the panel targets BRAF, whereas the other four target MEK1
or MEK1/2 (Supplementary Table 2). We selected M249R4 cells for study because of its robust
growth profile and strong resistance to Vemurafenib. Figure 13 shows typical results from two
individual experimental runs, while Figure 14 shows results from all repeats fitted to a sigmoid
dose response function, for reference. Control DMSO-treated cells exhibited a median growth
rate of ~2.5% per hour at 0.1% DMSO concentration (v/v), decreasing slightly to 2% per hour at
higher concentrations (0.3%-0.5% v/v). For each targeted kinase inhibitor, the peak tolerated
serum concentration (Cmax (ng/mL)), as measured in clinical trials, is shown on the dose-response
curves by an asterisk (*). See Supplementary Methods for Cmax determination detail. As
expected for this highly Vemurafenib-resistant line, the BRAFi Dabrafenib showed no growth
inhibition as compared to the DMSO control. The MEK1 inhibitor Cobimetinib and the MEK1/2
inhibitor Trametinib were the most effective growth inhibitors: Cobimetinib completely arrested
median sample growth at 0.255 μM concentration, which is roughly one half of the maximum
tolerated serum concentration, while Trametinib arrested growth at a concentration between 4
nM and 40 nM, or between 1/10x and 1x Cmax. MEK1/2 inhibitor Selumetinib arrested growth at
2.55 μM, equal to 1x Cmax, while MEK1 inhibitor Binimetinib failed to halt growth at
concentrations below 2.91 μM, or 5x Cmax, suggesting that Binimetinib would be an unlikely
candidate for salvage therapy in this simulated case.
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Figure 13. Effects of kinase inhibitors on Vemurafenib-resistant melanoma as measured by
HSLCI. M249R4 cells were plated into 24-well plates and dosed at increasing concentrations
of each inhibitor. After 24 h of incubation, the plate was imaged by HSLCI continuously for
10 h. Typically, four different doses for each inhibitor, and four DMSO controls, were
measured in each run simultaneously. Data in the figure represent two typical experimental
runs, using different dose gradations. Hourly growth rates were automatically calculated for
individual cells in each sample by linear fit to the biomass vs time data. Each box plot
summarizes the hourly growth rates of a population of cells exposed to escalating
concentrations of each drug. Individual dots in the underlying scatter plots represent the
growth rates of single cells. Boxplot notches are indicative of 95% confidence intervals for
the medians. Median number of cells per well: top panel 159 (range 79–216); bottom panel
160 (range 59–294).
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Figure 14. Summary of effect of five kinase inhibitors on Vemurafenib-resistant melanoma as
measured by HSLCI. M249R4 cells were plated into 24-well plates and dosed at increasing
concentrations of each inhibitor. After 24 hours incubation, plates were imaged by HSLCI
continuously for 10 hours. Hourly growth rates were automatically calculated for individual
cells in each sample by a linear fit to the biomass versus time data. Data for each drug-dose
combination shown represents a sum of three independent replicates. Each boxplot
summarizes the hourly growth rates of a population of cells exposed to escalating
concentrations of each drug. Individual dots in the underlying scatter plots represent the
growth rates of single cells. Boxplot notches are indicative of the 95% confidence intervals for
the medians. Median population growth rates from all kinase panel repeats are plotted and
fitted with sigmoid curves. Error bars indicate the 95% confidence intervals for the medians.
The doses indicated by an asterisk (*) correspond to the maximum serum concentrations
(Cmax) measured in the blood during clinical trials at FDA-approved therapeutic doses. Median
number of cells tracked per well per replicate was 159 (range 79 - 294).
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3.4 Discussion
Here, we demonstrated the ability of our rapid HSLCI platform to quantify individual cell drug
sensitivity in tumor cell populations. This quantification may provide critical data for treatment
selections on a whole-tumor population level and can identify specific subpopulation drug
sensitivities to predict drug resistance at a single cell level. Our results also show the
reproducibility of two similar but distinct implementations by obtaining concordant data from
two institutions with independently constructed and standardized HSLCI platforms. This twocenter study design is unique amongst live cell response profiling approaches and provides
confidence that the newly configured HSLCI has the required consistency for further
development towards a clinically useful approach.
In comparison to other single live cell biomass profiling approaches, including our own prior
interference microscopy studies, HSLCI represents a substantial technical advance in single cell
sampling throughput, cell tracking duration and parallel measurement of multiple
agents.34,36,74,78 For example, Stevens et al. recently used micro-channel resonators to
demonstrate that the combined measurement of single cell mass and growth rates could be
used to identify drug resistant cells isolated from an engineered mouse AML model.28 Their high
throughput ‘next-gen’ system with 12 micro-resonators could measure up to 60 cells per hour,
where cells are measured serially, each for 15 minutes, resulting in simple ‘snapshots’ in time.
Unfortunately, tumors that grow in small clusters or clumps, as do many melanoma samples, are
inaccessible to this platform unless they are disaggregated, which affects their growth
characteristics and drug sensitivity. In contrast, HSLCI typically measures between 10 3 and 104
cells in each experiment, tracking each cell individually for hours to days, and is well suited to
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tumors that grow in clusters or clumps without disaggregation. In addition, identifying rare
resistant clones in a population of normal or therapy-sensitive malignant cells will require deep
sampling. For instance, typical minimal residual disease detection using multi-color flow
cytometry requires sampling to a depth of at least 104 and up to 106 cells.124 We believe that
realistic improvements may allow HSLCI throughput to approach 105 cells per experiment.
Due to the mechanical and environmental stability of the HSLCI system, we have been able to
track single cells and cell clusters for up to 10 days, with no time limit yet found. This is a
dramatic increase over our previous 12-hour maximum duration interference microscopy work,
and enables studying behaviors that evolve over many minutes, hours or days, encompassing the
vast majority of cellular responses. Cell tracking duration is of direct relevance to detecting drug
responses in cells isolated from patients, as it is necessary to distinguish between growth-arrest
(cytostasis) and death resulting from drug exposure versus other influences. With HSLCI this is
accomplished by repeatedly observing individual cells before and after drug exposure-response,
a process that requires several hours or more.
The primary drawback of HSLCI compared to microscopic, single cell ‘snapshot’ fluorescent
assays and micro-resonator mass assays is the relatively large data footprint and extensive image
analysis required to generate a biologically interpretable result. At present, data analysis time,
not hardware capability, is throughput limiting. On the other hand, the single cell images
generated by HSLCI are inherently information rich, allowing not only mass accumulation but
cytokinesis, motility and cell shape information to be quantitated. Integrating these mutually
supporting metrics will be a direction for future research. Furthermore, system upgrades can be
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largely accomplished by software rather than hardware modifications, making the upgrade path
efficient and flexible.
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Chapter 4
CD3+ T Cell Mass Dynamics During Stem Cell Transplantation
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4.0 Chapter Overview
This chapter details the use of LCI to analyze T cells extracted from the blood of patients
undergoing stem cell transplantation at VCU’s Massey Cancer Center. This project was planned
and executed in close collaboration with Dr. Amir Toor and Dr. Catherine Roberts. The text and
figures that follow have been adapted (reproduced with permission of The Royal Society of
Chemistry and co-authors) from a publication of the study’s results, first-authored by K. Leslie, in
the journal Analyst.125,126
4.1 Introduction
Approximately 32,000 allogeneic stem cell transplants (SCTs) from HLA-matched donors are
performed annually.127 In addition to an increased susceptibility to infection, recipients of these
transplants face competing risks of malignancy relapse and graft versus host disease (GVHD). In
HLA-matched SCT recipients, GVHD results from the recognition of recipient minor
histocompatibility antigens by donor T cells. Despite an evolving understanding of the
complexities of these alloreactive T cell responses and significant reductions in non-relapse
mortality (NRM), the incidence of GVHD ranges from approximately 10% to 50% for allogeneic
SCT recipients.128 This is particularly problematic as an increasing number of SCTs are performed
each year, matched unrelated donors are utilized in more than half of allogeneic transplants, and
increasingly older patients now undergo transplantation using reduced-intensity conditioning
where a graft versus tumor (GVT) effect is critical for disease control and GVHD is especially
deleterious. Furthermore, no reliable laboratory measures have yet emerged to allow real-time
titration of post-transplant immunosuppression on an individualized basis to modulate
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competing GVHD and cancer relapse risks. Essential to the development of such measures is an
improved understanding of the immunobiological mechanisms underlying discrepancies in GVHD
incidence, such as further characterization of the biological diversity of transplant donors and
recipients, and efforts to identify a comprehensive marker of post-transplant alloreactivity.129,130
Given the central role of T cell growth and differentiation in SCT, and that of processes known to
alter cellular size and shape, one approach to studying alloreactivity in real-time might involve an
assessment of donor-derived T cell biophysical properties. It has been shown in vitro that CD8+
murine T cells increase their mass upon activation and, further, that cytotoxic T cells transiently
increase their mass when effecting cell killing, in a stylized cell culture system.58,131 Mathematical
modeling by Toor et al. has identified distinct population growth kinetic signatures of
lymphocyte recovery that correlate with levels of donor-derived CD3 + T cells and
alloreactivity.132,133 Further, it has been shown that there are significant metabolic adaptations in
T cell subsets upon engagement of an antigenic peptide-HLA complex by the T cell receptor.
These metabolic changes include increased glycolysis and oxygen consumption as well as
cytokine production.134 Higher levels of GLUT 1 expression have been observed in activated T
cells, again suggesting increased metabolic & biosynthetic rates.135 Indeed, a weak correlation
has been shown between intracellular ATP concentration in T cell subsets and severity of clinical
GVHD in humans and between increasing glycolysis and GVHD in murine models.136,137 These
results suggest that T cell activation and consequent metabolic, biosynthetic, and, logically, mass
changes, may correlate with significant functional events in the SCT immune reconstitution
process, as donor-derived T cells experience a new antigenic milieu, post-transplant.
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At the time of this study, the HSLCI was still under development. Therefore, using the lowerthroughput LCI system, we measured biomass in populations of CD3 + T cells isolated from
hematopoietic stem cell transplant patients, at various times pre and post-transplant, with an
aim to identify kinetic signatures associated with immune reconstitution and GVHD.
4.2 Methods
Consecutive patients undergoing myeloablative conditioning and stem cell transplantation
between May 2015 and May 2016 were enrolled on a prospective study approved by Virginia
Commonwealth University's Institutional Review Board (VCU-IRB #HM20004916) (Table 1).
Patients gave informed consent for stem cell apheresis product and whole blood sample
collection, and for rabbit anti-thymocyte globulin (Thymoglobulin) either 3.5 mg kg−1 (MRD) or 5
mg kg−1 (MUD) starting from day-3 to day-1. GVHD prophylaxis was with either tacrolimus or
cyclosporine in combination with methotrexate (MTX) or mycophenolate mofetil (MMF).
Antimicrobial and antifungal prophylaxis was administered. Routine surveillance for
cytomegalovirus (CMV) and Epstein Barr virus (EBV) was carried out using PCR. Donor cell
chimerism was studied using short tandem repeat sequence PCR. Average T cell chimerism for
allogeneic transplant recipients was 90% at 30 days post-transplant (T30), 99% at 60 days posttransplant (T60), and 99% at 90 days post-transplant (T90). Donor-derived CD3 + T cell (ddCD3)
counts were calculated as previously reported.130 Average ddCD3 cell counts were 571 cells per
μl, 1417 cells per μl, and 1019 cells per μl at 30, 60, and 90 days post-transplant, respectively.
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Patients have had a median follow up

Table 1. Patient demographics
n=18
49 (24-65)

Median Age, y (range)
Gender

of 11 months (range: 0.27–15.7)
following SCT. Of the patients that

Female

9

Male

9

underwent allogeneic SCT, 9 (69%)

Acute lymphoblastic leukemia

3

developed either acute or chronic

Hodgkin's lymphoma

2

Myelodysplastic syndromes

4

Chronic myelogenous leukemia

1

Non-Hodgkin's lymphoma

3

Acute myeloid leukemia

2

Multiple myeloma

1

Myelofibrosis

2

Disease

Donor Type

GVHD. Median onset of acute GVHD (n
= 7, 6 MUD recipients) and chronic
GVHD (n = 4, all MUD recipients) were
at 58 and 126 days post-transplant,

Matched unrelated

11

Matched related

3

Autologous

4

Conditioning Regimen

respectively. The incidence of grade
3–4 acute GVHD was 15% and the

TBI/Cyclophosphamide

2

Busulfan/Cyclophosphamide

6

Busulfan/Fludarabine

4

Fludarabine/Melphalan

2

BEAM

3

Melphalan

1

occurred in one MUD recipient and

+/+

7
3

CMV/EBV reactivation developed in

+/-/+

4

-/-

0

incidence of moderate to severe
chronic GVHD was 23%. Relapse

CMV Status (Donor/Recipient)

GVHD Prophylaxis
Tacrolimus-Methotrexate

6

Tacrolimus-Mycophenolate mofetil

4

Cyclosporin A-Methotrexate

2

Cyclosporin A-Mycophenolate mofetil

1

Median CD34 Dose (E6 cells/kg) (range)

4.59 (3.11-9.40)

nine and five (6/3, 4/1 MUD/MRD)
patients, respectively. Seven of eleven
MUD recipients are surviving, as are all
MRD and autologous SCT recipients.
Post-transplant, two patients

*Scheduling and dosing for conditioning regimens w ere as follow s:
•TBI/Cy 2 Gy TBI in 6 fractions bid days -6, -5, -4; Cyclophosphamide 60mg/kg/day days -3, -2
•Bu/Cy Busulfan 0.8 mg/kg for 16 doses days -7, -6, -5, -4, -3; Cyclophosphamide 60 mg/kg/day days -3, -2
•Bu/Flu Fludarabine 40 mg/m2 days -5, -4, -3, -2; Busulfan 130 mg/m2 days -4, -3, -2
2

2

•Flu/Mel Fludarabine 30 mg/m days -6, -5, -4, -3; Melphalan 140 mg/m day -2
•BEAM Carmustine 300 mg/m2 day -7; ara-C 100 mg/m2) for 8 doses days -6, -5, -4, -3; Etoposide 100mg/m2
for 8 doses days -6, -5, -4, -3; Melphalan 140 mg/m2 day -2
•Melphalan 200mg/m2 day -2
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diagnosed with GVHD later died; after

suffering multiple infections, one patient that remained GVHD-free died.
Cell Mass Measurements
Donor samples were obtained for mass measurement from apheresis products, with a 2 mL
aliquot provided for each patient. Transplant recipient whole-blood samples (3 mL) were drawn
at 14 ± 3, 28 ± 3, 56 ± 3, and 100 ± 3 days post-transplant. After acquisition, whole-blood
samples were stored at +4 °C for no longer than four hours prior to cell isolation. CD3 + T cells
were isolated directly from donor products and patient whole blood samples using the
Dynabeads FlowComp Human CD3 Kit (ThermoFisher). Isolated cells were resuspended in 500 μl
sterile phosphate-buffered saline.

Figure 15. Sample
preparation and analysis
procedure.
A) Immunomagnetic beads
were used to isolate CD3 + T
cells from patient whole
blood or donor apheresis
product samples. B)
Histogram of CD3 + T
biomass distribution from a
representative sample. C)
Typical quantitative phase
image of CD3 + T cells.
Height and coloration are
proportional to optical
thickness.

For mass imaging, isolated CD3 + cells were transferred to optical glass-bottomed cell culture
dishes to a maximum concentration of 1 × 106 cells per mL in a 3 mL volume of sterile PBS (Figure
15-A).
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Measurements were taken using a 40X objective (Nikon, NA 0.75) under standard cell culture
conditions (37 °C, 5% CO2). The mass of each cell was calculated by taking the median of 20
individual mass measurements. Figure 15-B shows a representative histogram of single T cell
masses found in a patient. The mass distribution was roughly symmetrical, with most median
masses between 60–80 pg, and intra-patient variation of roughly 30 pg. Figure 15-C shows a
typical field of view rendered as a 3D image, with height corresponding to local mass density or
‘optical thickness’. Individual cells appeared as extended spheres of varying density, therefore
cellular diameter alone was not a good predictor of overall mass.
4.3 Results
T cell mass population medians for each sample are presented in Figure 16 as a function of time
post-transplant. We found a pronounced rise in median T cell biomass vs. infused product
(median +25%; p < 0.001; Student's t-test) shortly after transplant (day 14), which moderated by
day 60. Further, the inter-patient and intra-patient cell masses were most variable at days 14
and 30 post-transplant in both allogeneic and autologous SCT recipients (data not shown), when
the ddCD3 count was the lowest. This is certainly consistent with the notion of a larger
proportion of T cells post allograft being activated due to the inflammatory milieu resulting from
conditioning related tissue/endothelial injury, infections and, in allogeneic transplant recipients,
GVHD developing post-transplant.138,139
Our group has previously reported that lymphocyte count and CD3 + cell recovery posttransplant occurs as a logistic function of time, with exponential expansion occurring in the first
few weeks following transplantation.133 The observation that T cell mass is high at these early
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time points is consistent with the notion that higher mass may be observed in proliferating T
cells. The initial peak and then later plateau effect seen in our T cell mass observations is also
reflected in T cell growth kinetics recorded following viral infections, which again has to do with
antigen-driven

Figure 16. Biomass of patient-derived CD3+ T cells post-transplant. Median CD3+ T cell
masses for all patients, grouped by time of sample acquisition (days post-transplant). Each
point represents a single patient per time point; autologous transplant patients (green
squares), allogeneic transplant patients (circles). For the allogenic transplants, white
circles indicate an absence of GVHD during the course of the study, while black circles
indicate a diagnosis of GVHD. Solid black lines indicate the average T cell mass for all
patients at the specified time point. Bars above and below the data points indicate
significant median cell mass differences between all patients at two different time points
as calculated by Student t-tests.

proliferation.140 An alternative interpretation is that this high T cell mass in the first days reflects
the effect of a ‘cytokine storm’ following SCT.141 Further, the lympho-depleted milieu of the early
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post-transplant period may also contribute to the rapid growth of T cells and mass acquisition. In
future studies, as T cell mass is measured, markers of proliferation will have to be assessed
simultaneously to discern the effect of proliferation vs. T cell activation. Patients who developed
GVHD tended to have persistently elevated or increasing masses at days 60 and 100 compared
with their infused product T cell mass. Patients with GVHD exhibited a

Figure 17. Biomass and GVHD grade
of patient-derived CD3+ T cells 60
and 100 days, post-transplant.
Median masses by GVHD status and
transplant type, normalized to the
mass of the T cells infused into the
patient. Each data point represents
the median CD3+ T cell mass for one
patient at a specified time point.
Roman numerals indicate maximum
acute GVHD grade, if present.
Maximum severity of chronic GVHD
is expressed as either mild,
moderate, or severe, if present.
Points with a contrasting center
indicate patient is now deceased.

significant (p = 0.006; Student's t-test) difference between product and day 100 normalized
median masses, showing a persistent elevation (∼18% higher median T cell masses than infused
stem cell product) beyond day 30. Five patients exhibited a 20% or greater increase in median T
cell mass at day 60 or 100, two of whom developed grade III–IV acute GVHD and one, severe
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chronic GVHD (Figure 17). A representative example of one of these five patients is contrasted
with a patient who did not develop GVHD, in Figure 18.

Figure 18. Boxplots showing normalized T cell population mass distributions, over time, for
two representative allogeneic transplant recipients. Product, Day 30, Day 60, and Day 100
mass measurements were normalized to the median mass of the patients’ product
samples. All individual cell masses (blue dots) measured at a given time point have been
overlaid onto that time point’s boxplot. A) Patient did not develop clinical signs of GVHD
during the course of the study. Median CD3+ T cell mass increased at day 30, but
decreased and stabilized through days 60 and 100. B) Patient developed severe chronic
GVHD involving the lungs 151 days post-transplant. Median CD3+ T cell mass increased
44% above the product sample median at day 30, and remained elevated through day 100.

Finally, one of our patients, a 24-year-old male with Hodgkin's Lymphoma, suffered Grade III
aGVHD and exhibited normalized median T cell masses of 32% (day 60) and 25% (day 100)
greater than the infused stem cell product. The initial cell mass increase was coincident with
Epstein Barr virus and Cytomegalovirus reactivation. Another, a 65-year-old male with
Myelodysplastic Syndrome, was diagnosed with severe cGVHD and exhibited median T cell
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masses 36% and 45% greater than infused stem cell product cells at days 60 and 100,
respectively. Both patients later died.
4.4 Discussion
If this observation is validated in a larger cohort, T cell biomass could become invaluable as an
inexpensive biomarker of alloreactivity and GVHD risk, and be used to guide decision making
about intensity of immunosuppression post-transplant. This may also be a useful adjunct to PCRbased diagnosis of viral reactivation, where low level reactivation often raises the conundrum of
whether toxic therapy should be initiated or held off on. Patients with high mass T cells in these
instances may indeed be in the process of mounting a protective response and may be followed
without introduction of cytotoxic drug therapy. Increasing the post-transplant sampling
frequency would also be beneficial in order to account for the variability in onset of GVHD
symptoms and better mitigate the effects of infections, viral reactivation, and relapse on T cell
mass. Importantly, continued development of GVHD predictive models using T cell mass-based
methodology must account for such potential confounding effects on this measure. However,
contextualizing T cell mass measurements with conventional clinical manifestation of infections
and GVHD, as well as with biomarkers, may allow real time titration of immunosuppressive
therapy.142
In order to simultaneously develop a more precise view of post-transplant alloreactivity and
elucidate underlying immunobiological mechanisms, it will be necessary to go beyond CD3 + cell
isolation and characterize relevant T cell subsets within each sample. Based on prior work by
Meier et al. and Berrie et al. that highlight normal reconstituting T cell diversity and identify the
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emergence of a limited number of dominant T cell clones in patients with GVHD, simultaneously
assessing T cell clonality and mass during immune reconstitution could enhance the specificity of
any predictive signatures.143–146 Cell mass spectra might also complement other modalities,
including newly vetted biomarker panels for NRM and GVHD, such as those developed by
Hartwell et al., as well as donor-derived T cell counts, lymphocyte reconstitution kinetics, and
predictive modeling of minor histocompatibility antigens.147 Our findings underscore the notion
that alloreactive T cell response is a multifaceted reaction of the donor T cells to the recipient
milieu. Aside from proliferation and T cell subset differentiation, there are critical metabolic and
functional changes associated with antigen recognition, which may result in biomass change.148 T
cell subsets are of crucial importance to GVHD pathophysiology, therefore, measurement of T
cell (and T cell subset) mass is a simple, clinically applicable parameter that summarizes the
latter two adaptations of T cells to the change in the ‘antigenic landscape’.149 Despite a small
patient cohort, results from this study provide the foundation for the continued assessment of T
cell population mass in understanding and predicting metabolic changes in the T cells associated
with alloreactivity and, subsequently, providing guidance for immunosuppression titration in
allogeneic SCT recipients.
The cell mass measurement method we use is one of many available options, each of which has
strengths and weaknesses depending on the application. The technical performance of the
phase sensing camera employed has been well documented by the manufacturer in a series of
papers.26,79,80 Our results suggest that other quantitative phase microscopy modalities, in
particular digital holography, could be employed for this application with success.150,151 Our LCI
system was automated for ease of use and reproducibility, but would not be considered high55

throughput. Improving the throughput and robustness of quantitative imaging platforms is an
important direction of research for the field.
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Chapter 5
Applications in Basic Research
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5.0 Chapter Overview
This chapter details experiments investigating apoptosis in established cancer cell lines, the
kinetics of degranulation in mast cell populations, and cell growth patterns in genetically
engineered Kaposi’s sarcoma cells during the latent-lytic switch of an oncogenic virus.
5.1 Apoptosis Assays
5.1.1 Introduction
As previously discussed, LCI’s utility hinges on the ability to correlate biological events of interest
with changes in the mass of the cells being observed. Experiments designed to validate these
correlations are typically conducted using LCI in parallel with established analytical methods.
Considering our initial goal of assessing the response of cancer cell lines to cytotoxic drugs, the
ability to quantify cell death in terms of changes in mass was an important early milestone.
Cell death can occur as a result of internal processes like cell aging or external factors like acute
injury or disease and, further, can proceed via several mechanisms.152 Injury and disease typically
cause cells to die by necrosis, while certain drugs, immune cell killing, cell aging, and mitotic
errors result in programmed cell death via apoptosis or autophagy.153–155
Of the cell death mechanisms, apoptosis is particularly dramatic owing to its irreversible nature
and array of associated morphological changes.156 Commercially-available kits can detect
different stages of apoptosis using cytotoxic chemicals and fluorescent dyes, allowing
researchers to understand the impact of specific conditions or drugs on a given cell.157 By
coupling LCI and fluorescent imaging, we hypothesized that the induction of apoptosis and
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subsequent cell destruction would result in significant decreases in mass that correlated with
appropriate fluorescent dye signals. Based on this hypothesis, we designed an experiment to
evaluate the correlation between mass loss and fluorescently-indicated apoptosis in established
lung (A549), kidney (786-0), and breast (MCF7) cancer cell lines.
Briefly, cells would be exposed to the apoptosis-inducing agents Actinomycin D and
Camptothecin in the presence of the fluorescent dyes YoPro1 (YP1) and Propidium Iodide (PI).158
YoPro1 is a DNA-intercalating dye that fluoresces green; PI is a DNA-intercalating dye that
fluoresces red.159,160 Both dyes enter cells through plasma membranes whose structures have
been compromised due. Because apoptosis triggers morphological changes that compromise a
cell’s plasma membrane, these dyes can enter and bind to DNA. Importantly, as the smaller of
the two dyes, YP1 is capable of entering dying cells earlier than PI. Taken together, we would
expect that cells exposed to Actinomycin D and Camptothecin, in the presence of YP1 and PI,
would simultaneously exhibit a detectable loss of mass while first fluorescing green and then red.
5.1.2 Results & Discussion
Control groups in each of the three lines exhibited steady single-cell growth rates of 2%/hr (MCF7), 2%/hr (786-0), and 3%/hr (A549). As expected of cultured populations, ~5% of cells in each
control group were non-viable as evidenced by detectable YP1 and PI fluorescence.
Treatment groups for each line exhibited pre-dosing growth rates similar to controls. After
dosing, median mass lost per cell ranged from 10-60%. Line A549 responded both more robustly
and more quickly than the other two lines, with PI fluorescence visible in almost all cells within
140 minutes of treatment and median mass loss per cell of approximately 40%. In line 786-0, PI
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fluorescence was similarly visible for all cells by 200 minutes, post-treatment, with a median
mass loss of 30%. Finally, line MCF-7 exhibited the slowest response, with PI fluorescence visible
in all cells at approximately 450 minutes after dosing. Results are summarized in Figure 19.
Data show a correlation between the timing of drug-induced apoptotic mass loss and PI
fluorescence in all three lines measured. However, variation between the extent and the timing
of mass loss between cell lines was apparent. Interestingly, the longer the published doubling
time for each cell line, the longer the amount of time required to induce mass loss and
fluorescence. While the underlying mechanism behind this observed disparity in timing is
unclear, our results demonstrate a clear link between the timing of cell mass loss and the
fluorescence of established markers following exposure to inducers of apoptosis.
5.1.3 Methods
For each experimental replicate, cells were seeded at 5 x 104 cells/ml in a 25 cm2 diameter
optical-glass-bottomed dish and allowed to grow for 24 hours in appropriately-supplemented
RPMI 1640 or DMEM-based media under standard mammalian cell culture conditions (5% CO2,
37 ⁰C). Media was exchanged 24 hours after plating. After the media exchange, the dish was
placed on the sample stage in the LCI system for one hour to reach thermal equilibrium. YP1 and
PI were added to the dish to final concentrations of 1 μM and 1μg/mL, respectively. After dosing,
brightfield, fluorescence, and phase images were collected for one hour, at 10X magnification, in
a 3x3 grid pattern to measure baseline growth rates. After one hour, 1X concentrations of
Actinomycin D and Camptothecin were administered, and imaging proceeded for an additional
800 minutes.
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Figure 19. Correlation of apoptosis, PI fluorescence, and mass loss in three cancer cell Lines.
Established cancer lines A549 (lung), 786-0 (kidney), and MCF-7 (breast) were measured for
400 minutes using LCI. 60 minutes after the start of imaging (vertical dotted blue lines),
treatment group cells were dosed with Actinomycin D and Camptothecin to induce apoptosis.
The upper panel depicts mass vs. time scatter plots of each individual cell tracked during a
single experimental replicate. Blue lines represent the median normalized mass of all cells at
each time point, while black lines represent the bounds of the 95% confidence interval for the
median. The lower panel depicts total red channel fluorescence intensity (i.e. the PI signal)
over time for each location (individual lines) imaged in a given sample. Note: the brief spikes
in fluorescence intensity following treatment represent a temporary recovery by fluorophores
from photo bleaching. Median number of cells measured in each replicate was 109.
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For each cell line, one control (media vehicle) and three treatment replicates were performed.
To ensure consistency and enable troubleshooting, the temperature and CO2 concentration in
the incubator (as well as the Z focus position of the objective) were logged during each
experiment. These measurements are critical because fluctuations in any of the three metrics
can alter the mass measured by the LCI, either by actually impacting the biological health of a
cell, or producing out-of-focus images that result in artificially high or low measurements.
5.2 Mast Cell Biology
5.2.1 Introduction
Mast cells are multifaceted components of the immune system best known for their role in
mediating allergic responses.161,162 They are found in almost all tissues of the body, including the
skin, gastrointestinal tract, respiratory mucosa, brain, and peritoneal cavity.163 Capable of
responding rapidly to stimuli, mast cells contain an array of effector molecules (mediators),
including histamine, serotonin, and multiple cytokines.164–166 The majority of these mediators are
packaged into granules and, upon a cell receiving a sufficient signal to “degranulate,” are
released.167 Effects of mediator release are numerous, including changes in the permeability of
blood vessels and the recruitment of immune cells.161 In addition to their role in normal
physiological responses, mast cells are implicated in wide range of conditions and diseases,
including cancer, cardiovascular disease, obesity, and autoimmune diseases.168–172
Degranulation is the process by which mast cells release their array of preformed mediators. The
process can be initiated through a variety of pathways, though the most common is IgEmediated.173–175 Briefly, mast cells express FcεRI, a high-affinity receptor for IgE, on their
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surfaces. IgE binds to FcεRI receptors and, when bound by its specific antigen, results in the
crosslinking of multiple FcεRI receptors. This crosslinking triggers a signal cascade that ultimately
results in the release of intracellular calcium and, subsequently, degranulation.176 Once
degranulation has been initiated, granules move to the mast cell’s membrane, fuse, and release
their contents. This entire process occurs in minutes and is accompanied by striking
morphological changes.177–179
As degranulation plays a central role in mast cell activity, studying its biological underpinnings
enables both a better understanding of mast cells’ roles in disease and our ability to develop new
therapeutic interventions.180 Of particular relevance are characterizing the quantities of
mediators released and the recovery period required between successive triggering events.181–
183

Literature on the latter is sparse, with one study suggesting an approximately 48-hour

recovery period in murine bone marrow-derived mast cells.179 Research laboratories commonly
measure degranulation by fluorescently tagging released effector molecules like histamine,
prostaglandin D2, beta-hexosaminidase, or IL-6 and then quantifying fluorescent signals.184 This is
a useful “endpoint assay” approach, but it precludes labeled cells from being using in
downstream experiments and requires bulk averaging of signals from cells in a population.
Our goal, in close collaboration with Dr. John Ryan’s laboratory in the VCU Department of
Biology, was to evaluate LCI and HSLCI as label-free tools for studying mast cell biology. In the
process, we hoped to gain insight into how much mass was lost by mast cells undergoing
degranulation in response to various stimuli and how long it takes for them to recover from this
process.
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5.2.2 Approach
Our approach centered around a robust characterization of mast cell population mass, size, and
behavior. A series of population-level and single-cell experiments were conducted. Briefly,
investigations of cell mass distributions and measurement reproducibility involved imaging
thousands of mast cells from distinct populations to examine intra- and inter-batch variation, as
well as differences between unprimed, primed, and triggered cells. Degranulation assays focused
on measuring mast cell masses before, during, and after the administration of known triggering
agents to examine response kinetics and recovery time. These assays were also conducted using
established fluorescent markers to correlate mass loss events with cell membrane disruptions
associated with degranulation. Two triggering agents were used: Ionomycin, a calcium
ionophore, and DNP-HSA, a biologically-relevant antigen.
5.2.3 Results
Cell Mass Distribution and Variation
Taken together, population-level studies revealed a consistently positively skewed distribution of
masses within a given mast cell population. Median masses ranged from 150-350 pg. The
distribution of cell masses in a representative population is show in Figure 20. Variation in pretreatment median masses between different cell batches was observed, with the largest median
masses measuring 2X larger than the lowest recorded medians. Experiments comparing the
masses of primed vs. unprimed cells from the same batch of cells revealed median masses in
primed cell populations to be 4-9% larger than unprimed populations.
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Figure 20. Distribution
of cell masses from a
single mast cell
population. Histograms
depicting the distribution
of mast cell masses from
a single population, as
measured by LCI. Cells
from the same
population were
measured during two
independent but
identical experimental
replicates (Repetition 1
and Repetition 2).
Median masses and total
cell counts (n) are
displayed in the top right
corner of each plot.

HSLCI Degranulation and Recovery Assays
HSLCI degranulation and recovery assays revealed the presence of two distinct groups of cells
based on cell size and mass (Figure 21). These groups were present in all samples and all
treatment groups. Interestingly, the smaller of the two groups remained essentially static
throughout the course of each experiment, neither gaining or losing mass or area. This group
was termed “Static.” The larger of the two, termed “Active,” exhibited growth in all experiments.
Further, a re-analysis of data from experiments conducted on the original LCI system revealed
the presence of these same two distinct populations of cells.
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Examples of both successful and unsuccessful DNP-HSA triggering of cells in the Active groups
are shown in Figure 22-A. An analysis of pre-treatment population median masses revealed that
degranulation was only detected in the two most massive mast cell populations (Figure 22-B). In
addition, in these responsive groups, a distinct pattern emerged in which treated cells rapidly
lost mass in response to DNP-HSA, then rapidly increased in size (area). Their size quickly
diminished to pre-treatment levels and the growth of the cells (in terms of mass and area)
resumed (Figure 23).

Figure 21. Distinct mast cell sub-populations. A) A scatter plot of cell mass vs. cell
diameter from a single time point (prior to treatment) during a representative HSLCI
experiment. Each point represents a single mast cell. Coloration was applied to highlight
the two populations (Green = “Active”, Gray = “Static”); data points are rendered semitransparent to enable visualization of density. B) A scatter plot of median cell mass vs.
time for the two groups, plotted with underlying lines depicting the best linear fits.

66

Figure 22. HSLCI-measured DNP-HSA response kinetics and inter-population mass
variation. A) Plot of median Active cell mass vs. time for three different representative
DNP-HSA response assay replicates, as measured by HSLCI. Dotted lines represent control
groups, while solid lines represent groups treated with DNP-HSA. Green coloration
indicates an experiment in which degranulation was successfully detected. Blue
coloration indicates that no degranulation was detected. Numbers and coloration
correspond to those shown in B. B) Bar plot of pre-treatment median masses from
independent HSLCI experimental replicates. As stated previously, coloration indicates
whether or not degranulation was measured in response to DNP-HSA treatment.
Experiment number is arbitrary and not reflective of chronological order. Median number
of cells measured for each experiment was 1422.
Figure 23. Active group mass and area versus
time. Representative plot of Active group
centroids from Triggered (DNP-HSA) and
Control BMMC populations, as measured by
HSLCI and identified using mixed model
fitting in MATLAB. Decreasing line
transparency corresponds with increasing
time. Time between successive data points is
identical. Note the rapid loss of mass and
increase in area, followed by recovery, in the
treated population.
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Correlation of Degranulation with Mass Loss and Fluorescence
Methylcellulose was successfully employed in short-term fluorescence correlation experiments.
Mass losses ranging from 20-50% were observed in hundreds of individual cells suspended in 1%
methylcellulose following the administration of Ionomycin. The appearance of fluorescent signals
from PI and YP1 correlated precisely with the decline of each cell’s mass, with YP1 (the smaller of
the two molecules) appearing several minutes prior to PI. A single-cell example is provided in
Figure 24.

Figure 24. Correlation of Ionomycin
dosing with mass loss and YoPro1
and PI Fluorescence in a single mast
cell. A scatter plot of cell mass vs.
time for a single mast cell.
Ionomycin was administered at T =
20 minutes. Fluorescence images A,
B, and C correspond to the time
points labeled on the scatter plot
indicating the appearance of green
and then red fluorescence.

Characterization of RBL-2H3 Degranulation and Recovery
Tumor line RBL-2H3 control and pre-treatment cells exhibited growth rates ranging from 2-5%
per hour. Cells treated with 1X DNP-HSA exhibited a rapid 30-50% decrease in mass within one
hour of dosing, while control cells grew unabated (Figure 25). Interestingly, mass lost by treated
cells was recovered within 1-3 hours, with cells continuing to grow steadily at 2-3% per hour for
18 more hours. In addition to their robust growth, many RBL-2H3 cells exhibited significant
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motility during the experiment’s 20-hour duration. This is consistent with behavior noted in
other studies.185

Figure 25. RBL-2H3 cell degranulation and recovery. Upper Panel) Cell mass versus time plot
for two representative RBL-2H3 cells. Cells were imaged using LCI for one hour, DNP-HSA or
media vehicle was administered, and imaging resumed for 11 more hours. The red line
represents the DNP-HSA treated cell. The blue line represents the Control (media vehicletreated) cell. Lines were smoothed using an interpolated spline function (fnplt, MATLAB).
Letters A-D and gray vertical lines correspond to selected time points for which cell images
are provided in the lower panel. Lower Panel) Images of the triggered and control cells
plotted in the upper panel, at time points A-D. White arrows indicate the cells whose
measurements are plotted.
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5.2.4 Discussion
Taken together, the data demonstrate LCI and HSLCI’s ability to reliably detect and measure
mast cell degranulation in the form of cellular mass loss, without the need for dyes or labels. At
present, HSLCI is best suited for population-level studies in mast cells due to its speed and multisample capacity, while the system’s single-cell tracking capabilities require refinement for this
cell type due to their rapid drifting in culture vessels. In the course of coming to these
conclusions, several important observations were made.
First, the presence of two distinct populations of cells was apparent in every experiment
conducted. It is unclear what, other than their size and growth behavior, differentiate the two
groups. Second, significant variation was seen in the median pre-treatment masses of Active
groups from different batches of mast cells. While all mast cell populations tended to
consistently exhibit a positively skewed distribution of cell masses, observed medians ranged
from 150 pg to 350 pg. Priming mast cells with IgE does not seem to contribute significantly to
this variation
Third, as previously mentioned, our HSLCI date indicate that mass loss due to DNP-HSA-triggered
degranulation was only detectable when median pre-treatment masses were greater than 225
pg. The majority of cell populations measured across our experiments had median masses lower
than this threshold. However, these same cell populations were successfully triggered using
DNP-HSA (as measured by IL-6 ELISA), at a variety of cell densities, in the Ryan lab. It is possible
that these response disparities might stem from a detection limit in our population-level
approach to measuring mass loss (Figure 26). A second explanation is that there is a minimum
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biological threshold for degranulation. Perhaps cell size and mass correlates with a measure of
maturity (i.e. sufficient mediator content) and, therefore, cells that are not mature (i.e. too
small, insufficient content) will not degranulate in response to FCεRI-mediated activation. This
explanation would fit with our data, but would need to be borne out using additional assays for
degranulation in light of the positive IL-6 ELISA.

Figure 26. Proposed model of mast cell degranulation. Two distinct sub-populations of
mast cells (“Active” and “Static”) were detected by LCI and HSLCI. Ovals represent the
respective range of cell masses and sizes measured in our data. Static cells do not grow or
respond in any detectable way to DNP-HSA. Active cells grow throughout each experiment
and, in some cases, exhibit mass loss and subsequent recovery in response to DNP-HSA.
Green arrows represent the change in mass and area of cells in the Active group in
response to DNP-HSA, when mass loss was detected. Based on our data, we hypothesize
that there is either an LCI detection limit and/or biological threshold of ~200 pg, below
which degranulation (in terms of mass loss) cannot be measured and/or does not occur.

Fourth, RBL-2H3 cells consistently exhibited a rapid recovery of mass (~90 minutes) following
degranulation. Regardless of the cause, RBL-2H3 cells behave differently from murine BMMC71

derived mast cells. As the tumor line is a familiar presence in mast cell research laboratories, a
more thorough understanding of its biology is warranted.
Mast cells play a multifaceted role of in allergy and disease. Providing a means by which to
assess degranulation, in addition to understanding the mechanisms that underlie the process, is
important for basic and translational research. These studies raise important questions about the
way in which degranulation is measured, and the effect that population variations, natural or
otherwise, affect the outcome of experiments.
5.2.5 Methods
Mast cells
All mast cells were provided by and obtained from Dr. Ryan’s laboratory at Virginia
Commonwealth University. Unless otherwise noted, cells were derived by the Ryan lab using a
Black 6 genetic background. Briefly, bone marrow cells are harvested from the femurs of the
mice. These cells are cultured with Interleukin 3 (IL-3) and Stem cell factor (SCF) for four to six
weeks, resulting in their differentiation into mast cells. These differentiated cells are
subsequently viable for experiments for up to eight weeks when maintained with continuous
supplementation of IL-3 and SCF in RPMI culture medium.
Triggering Agents
Cells triggered using DNP-HSA were first “primed” overnight using 100 ng/ml of mouse anti-DNP
IgE. Media was exchanged and cells washed prior to experimentation and exposure to DNP-HSA.
Cells triggered using Ionomycin did not require priming and, therefore, only a media
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Figure 27. Summary of triggering agent
mechanisms of action. Ionomycin and
DNP-HSA were used independently to
trigger degranulation in BMMCs.
Ionomycin is a calcium ionophore
capable of trafficking calcium directly
through mast cell membranes. DNPHSA binds to FcεRI -bound IgE
molecules, triggering FcεRI crosslinking
that results in a signaling cascade. This
signaling cascade causes the release of
calcium sequestered in the
endoplasmic reticulum. Degranulation
is triggered in both cases as a result of
the rapid increase in intracellular
calcium levels (Adapted from Nirmal et
al., 2013)
exchange was necessary prior to experimentation (Figure 27). Stocks of all triggering agents and
media were prepared and provided by the Ryan lab.
Population-level Dose Response Studies using LCI
Initially, population-level investigations of mast cell degranulation utilized the first iteration of
the LCI system. Mast cell responses to Ionomycin and DNP-HSA were assessed at multiple time
intervals and across a range of doses. In our inaugural experiments, cells were imaged by the LCI
in a custom, 4-well Teflon sample block. Briefly, two 20 mm x 20 mm hand-cut silicon squares
were prepared from silicon wafers and cleaned with 70% ethanol. One silicon square was placed
in the center of each of two wells, designated Control or Treatment, in the Teflon block. 3mL of
cells suspended in culture medium (5 x 105 cells/ mL) was then added directly to each of the two
wells. An optical imaging window was placed on top of each of the silicon chips.
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Response kinetics were measured in response to a 1X (1 nM) dose of Ionomycin. Cells in the
Treatment well were measured prior to dosing to establish a baseline distribution of population
cell masses. Ionomycin was administered after these baseline mass measurements, followed by
additional measurements every 5 minutes for 25 minutes. Imaging of the Control well was
conducted similarly, with the administration of a media vehicle control (6 μl) in place of
Ionomycin. Three replicates of this experiment were conducted.
Follow-on experiments examined our ability to resolve responses across a wide range of
Ionomycin doses. To accommodate an increased number of samples, cells were imaged on a
modified Teflon sample block (Figure 28-A). Three standard glass microscope slides () were
painted matte black and arrayed in parallel on the Teflon block’s surface. 20 mm x 20 mm handcut squares were prepared from silicon wafers, cleaned with 70% ethanol, and arrayed in a 2x3
grid pattern. 0.25 mm thick plastic shims were placed on top of each silicon chip. Number X glass
cover glass squares were then placed on top of each shim. The effective imaging area for each
sample using this arrangement of components was approximately 200 mm2. Mast cell responses
to Ionomycin were assessed across a log scale of doses (Figure 28-B). Briefly, 1 x 106 unprimed
mast cells were deposited on to each silicon chip and covered with cover glass. Pre-treatment
mass measurements were collected from each dosing group’s sample. Ionomycin was then
added to all samples at indicated doses and allowed to take effect for five minutes. Four images
at different locations within the sample well were taken for each dose condition. After
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Figure 28. LCI sample mount and dosing overview. A) Three standard glass microscope
slides were painted matte black and arrayed in parallel on the surface of the Teflon block’s
surface. 20 mm x 20 mm hand-cut squares were prepared from silicon wafers, cleaned
with 70% ethanol, and arrayed in a 2x3 grid pattern. 0.25 mm thick plastic shims were
placed on top of each silicon chip. Number X glass cover glass squares were then placed on
top of each shim. The effective imaging area for each sample using this arrangement of
components was approximately 200 mm2. B) Schematic of the sample imaging order and
dosing used in a single Ionomycin response assay replicate.

each dose group had been imaged, the imaging process was repeated for a second cycle.
Replicates of this experiment were performed three times. The order of imaging for dosing
groups was randomized for each replicate. These time interval and log-scale dose response
experiments were repeated, each in triplicate, with DNP-HSA (1X = 50 ng/mL) as a triggering
agent instead of Ionomycin.
Effects of IgE Priming on Mast Cell Mass
Investigations of Primed vs. Unprimed mast cells consisted of comparing cells from the same
initial population of mast cells. A group of viable cells was split and one half primed (as
previously described). The next day, cells from both groups were deposited and imaged on the
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modified, six-sample Teflon block (approximately 1500 cells measured per group). This was
repeated three times, with each replicate occurring on a different day.
Validation of LCI Measurement Reproducibility
Reproducibility validation experiments utilized fresh unprimed mast cells. 2 mL of 5 x 105 cells/
mL cell suspension was pipetted on to each of six silicon chips on the modified Teflon block and
covered with cover glass, as previously described. Four images were collected of each chip.
Immediately following this first imaging cycle, a second identical cycle was performed. This
experiment was performed in triplicate using different populations (different isolation days) of
mast cells.
Measurement reproducibility was further assessed by imaging fresh untreated cells on a single
silicon chip. 2 mL of 5 x 105 cells were deposited onto the chip and covered with cover glass, as
previously described. 25 images (5x5 grid pattern) were collected. After this first cycle, an
additional five imaging cycles were performed on the same sample. Three replicates of this
experiment were conducted, each using a different population of mast cells.
Single-Cell Degranulation Studies Using LCI
Experiments involving single-cell tracking utilized 35 mm, single-well, glass-bottomed dishes,
unless otherwise noted. A custom double-dish mount was constructed to enable the
simultaneous use of up to two of these dishes (i.e. Control and Treatment). Additionally, all mast
cell experiments described from this point forward utilized a Phasics camera to acquire mass
measurements (as opposed to the modified Michelson interferometer described previously).
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Proof-of-concept cell immobilization studies were conducted using 2.5 ml of fresh untreated
mast cells suspended to a final concentration of 5 x 105 cells/mL in a 1% methylcellulose solution
prepared using complete RPMI culture medium. A 4x4 grid of images was collected by the LCI
every 10 minutes for 16 hours. Phase images were processed as previously described to
generate mass measurements for individual mast cells.
Fluorescent imaging studies (summary provided in Supplementary Table 3) designed to correlate
mass loss events with degranulation were performed as follows. 2.5 mL of fresh untreated mast
cells were aliquoted and 1X concentrations of YoPro1 (YP1) and Propidium Iodide (PI) were
added. A 1% methylcellulose solution was prepared using complete RPMI culture medium. Dyed
cells were suspended in the solution to a final concentration of 5 x 105 cells / ml. This cell
suspension was transferred to a single 35 mm glass-bottomed dish and incubated under
standard cell culture conditions for one hour. After incubation, the dish was transferred to the
LCI. Image collection was initiated in a 2 x 2 grid, with brightfield, fluorescent, and phase images
being collected in rapid succession at each location. Ionomycin was administered to the sample
at 1X after approximately 20 minutes of imaging. Post-dosing, imaging continued for eight hours.
Three replicates of this experiment were performed. Variations of this experiment were also
conducted using DNP-HSA instead of Ionomycin.
Phase images from these fluorescent imaging studies were processed as previously described to
generate mass measurements for individual mast cells. Fluorescent images were separated into
individual RGB channels, with each channel being subsequently analyzed to track intensity over
time for regions of interest identified by MATLAB’s otsu thresholding function.
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Experiments with the adherent rat basophilic leukemia cell line RBL-2H3 were performed as
follows. RBL-2H3 cells were obtained from the Ryan lab and immediately deposited in provided
culture medium to a final concentration of 2 x 105 cells/mL in two glass-bottomed dishes. Dishes
were placed in a cell culture incubator overnight to allow time for cell adherence to the dish
surface. After incubation, dishes were transferred to the LCI system and allowed to reach
thermal equilibrium for one hour. After one hour, 4x4 grids of images were collected from each
dish every 15 minutes for one hour, at which point one of the dishes received a 1X dose of DNPHSA. After dosing, cells were imaged for an additional 36 hours. This experiment was repeated
twice.
Measurement of Degranulation and Recovery
Experiments investigating the population-level mass kinetics of degranulation in response to
DNP-HSA were conducted as follows. Mast cells were primed overnight with IgE (as previously
described) by the Ryan lab. 3mL of primed cells in culture medium were deposited into each well
of a 24-well plate at a final concentration of 5 x 105 cells/mL. The plate was placed in the HSLCI
and allowed to reach thermal equilibrium for one hour. Imaging was conducted at a rate of 30
images/well every eight minutes for one hour, with plate tilting every 10 minutes. After one
hour, half of the wells in the plate were dosed with 1X (50ng/mL) DNP-HSA. After dosing,
imaging continued for an additional 39 hours. Replicates of this experiment were performed
seven times with moderate variations, including the simultaneous measurement of different
batches of primed cells or the inclusion of an unprimed population from which primed cells were
generated. Data generated by the experiments were filtered using manually-implemented
cutoffs for cell mass and area to remove spurious data points.
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5.3 Kinetics of KSHV Lytic Activation
Kaposi’s sarcoma (KS) is an incurable cancer associated with immunosuppression or
immunodeficiency, often occurring in patients with AIDS or those who have undergone organ
transplantation.186 It typically effects the skin, but can occur in the lymph nodes, gastrointestinal
tract, and major organs.187 The primary cause of KS is infection with human herpesvirus-8 (HHV8), also known as Kaposi’s sarcoma-associated herpesvirus (KSHV), which is commonly
transmitted via saliva.188 Briefly, after infecting host cells, KSHV’s latency program is activated by
default, resulting in the production of several important proteins that interfere with host p53
and retinoblastoma protein activity, ultimately compromising the cells’ genetic integrity.189,190
Certain signals can also activate the virus’ lytic program, during which it makes thousands of
infectious copies of itself and eventually destroys the host cell.191–193 KSHV is a particularly
interesting because of its possession of numerous human genes, its strong association with
multiple cancers, and its shared membership in the same viral family as Epstein-Barr virus.194
In collaboration with the Dr. Blossom Damania’s laboratory at the University of North Carolina’s
Lineberger Cancer Center, we conducted pilot studies on genetically-modified Kaposi’s Sarcoma
cells in an effort to evaluate HSLCI as a tool for studying the kinetics of lytic program activation in
KSHV. Our studies used iSLK.219 cells, a genetically engineered endothelial cell line containing
Doxycycline-inducible latent KSHV.195 These cells also contain two fluorescent markers: green
fluorescence protein (GFP), which is constitutively expressed, and red fluorescent protein (RFP,
which is expressed exclusively during lytic replication of KSHV. All cells, media, and reagents
were provided by the Damania lab.

79

Using this model, we aimed to study mass kinetics of iSLK.219 cells immediately after exposure
to KSHV-inducing Doxycycline. Briefly, 2 mL of 5 x 104 cells were dosed with Doxycycline (1
μg/ml) and imaged by HSLCI for 65 hours (once every 15 minutes); both phase and fluorescent
images were collected. Based on this approach, we would expect to see green fluorescence in
individual cells which transitions to yellow as KSHV lytic programs are activated and RFP
expression begins. This experiment was repeated three times (navg= 600 cells/experiment).
Several interesting trends were observed. First, as measured by the emergence of red
fluorescence, approximately 20-24 hours is required for Doxycycline to induce KSHV’s lytic
program. Second, three hours after lytic activation, cell growth ceased. This “static” period lasted
for approximately 30 hours, followed by a slow loss of mass and, finally, cell death. A
representative single-cell example of these observations is provided in Figure 29.
In addition to fulfilling their role as a proof of concept for our ability to conduct multi-day
fluorescent imaging runs, these experiments show that, at least in KSHV, lytic activation has a
distinct kinetic signature. This has implications for basic virology research as changes in cell
growth patterns can give clues to the involvement of specific pathways during the latent-lytic
switch. Further, it could provide a label-free metric of lytic activation for wild type cells. Beyond
KSHV, HSLCI could be used to study the kinetics of primary infection in across a range of viruses
and cell types.
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Figure 29. Single-cell Doxycycline-induced KSHV lytic activation. A representative plot of cell
mass versus time for a single iSLK.219 cell dosed at 0 minutes with Doxycycline. Individual
point coloration indicates the fluorescence color emitted by the cell (i.e. yellow indicates
simultaneous GFP and RFP expression, black indicates a lack of fluorescence). Note: iSLK.219
cells constitutively express GFP and contain latent, Doxycline-inducible KSHV virus. Induction
of the virus’ lytic program with Doxycycline also induces RFP expression.
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Chapter 6
Conclusions and Future Directions
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6.0 Chapter Overview
This chapter provides a summary of the work presented thus far, an overview of ongoing HSLCI
experiments, and a discussion of future directions.
6.2 Summary of Work Presented
Cell mass is emerging as an important indicator of cell health and status. Improvements in digital
imaging and processing technologies have enabled quantitative phase imaging to become a
precise method for non-invasively studying cell mass kinetics at the single-cell level. Our work
using the LCI and HSLCI systems has resulted in several important achievements. First, we have
demonstrated an ability to measure cells continuously for over 10 days. This is significantly
longer than similar QPI-based techniques and provides a sufficient window of time to observe
the vast majority of cellular processes. Second, we have demonstrated an ability to handle a
range of sample types on the same instrument, including single cells and clusters, non-adherent
and adherent cells, and established cell lines and patient samples. Third, the HSLCI has enabled
us to visualize unique mast cell populations and processes, as well as confirmed our ability to
conduct correlative fluorescent studies. Fourth, our work with melanoma validated LCI and HSLCI
in two independent laboratories. We demonstrated an ability to quantify heterogeneous
responses to therapeutics and discriminate between drug-sensitive and drug-resistant cells in
multiple patient-derived melanoma cell lines, adding to the body of evidence that the in vitro
measurement of cell mass after drug exposure can achieve the resolution and throughput
necessary to be clinically relevant. Finally, our pioneering work on T cell mass dynamics during
immune reconstitution revealed previously undescribed kinetics that could be informative in
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tailoring post-transplant immunosuppression. In summary, we have developed, validated, and
deployed a microscopy platform that has the potential to become a powerful tool in applications
from the bench to the bedside.
6.3 Ongoing Work
Work by several members of the Reed laboratory, including Graeme Murray and Daniel Guest,
have resulted in numerous improvements in HSLCI system performance (enabling imaging
speeds of 16 fps, 4X faster than described in our work on melanoma) and an expansion of its
applications. The following sub-sections describe ongoing HSLCI pilot projects.
6.3.1 Drug-Induced Cellular Senescence
Senescence, is a protective and stable state in which the cell cycle has been arrested in response
to a variety of signals, including telomere shortening, drug exposure, and the expression of
growth-promoting oncogenes.196 For previously-healthy cells, entering a senescent state can
help prevent the development of malignancies.197 In cancer cells, senescence induced by
chemotherapy or radiation treatments can have the opposite effect: promoting aggressive drugresistant phenotypes.198,199 As such, the characterization and quantification of therapy-induced
senescence is and urgent and important area of research for improving patient outcomes.
In collaboration with Dr. David Gewirtz in the VCU Department of Pharmacology and Toxicology,
our lab is conducting pilot studies on the mass kinetics of drug-induced senescence in cancer
cells. Briefly, H460 (lung carcinoma) cells are exposed to Etoposide, a chemotherapeutic used in
the treatment of a range of solid tumor and blood cancers. Following drug exposure, cells are
sorted into senescent and non-senescent groups by flow cytometry using an established
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fluorescent marker for cellular senescence (C12FDG, a modified substrate of β-galactosidase).200
Sorted groups are then imaged by HSLCI for up to six days to measure cell mass and detect
proliferative recovery. Three replicates of this experiment have been performed, to-date.
Our data indicate that cells sorted as “senescent” are 3-4X larger in mass and area than both
control cells and drug-treated cells that did not become senescent. These larger cells, though
theoretically growth static, exhibited mass accumulation rates of 1% per hour, while nonsenescent treated and control cells grew at approximately 3% per hour. In addition, a small
percentage of senescent cells eventually transitioned into a rapidly-growing (3% per hour) state
and, subsequently, divided at three or more days, post-treatment. While further experimental
replicates are required to confirm the reproducibility of these trends, the data demonstrate our
ability to detect changes in proliferative states and quantify the heterogeneity of responses in
senescent lung carcinoma cells. In addition to aiding the characterization of drug-induced
senescence as a process, this approach could help in screening new and existing therapeutics for
their propensity to promote drug resistance.201
6.3.2 Effect of Radiation on Endothelial Cells
Prostate cancer is the most commonly-diagnosed cancer in men.202 Treatment generally consists
of classical chemotherapy, hormone ablation, or radiotherapy (targeted radiation).203 Morbidity
and mortality vary significantly by socioeconomic status, ethnicity, and geographic location.204
Even taking into account disparities in access to medical care and screening, men of African
descent have significantly worse outcomes, including higher rates of radiation treatmentinduced side effects like erectile dysfunction and proctitis.205 Single-nucleotide polymorphism
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(SNP) and genome-wide association studies (GWAS) have both supported these observations.206
The underlying cause of many of the observed side effects and poor treatment outcomes is
radiation-induced damage to endothelial cells that make up critical vasculature around the
prostate.207,208
In this context, our lab is evaluating HSLCI, in collaboration with Dr. Ross Mikkelsen in the VCU
Department of Radiation Oncology, as a tool to measure the effects of radiation exposure in
endothelial cells. These pilot studies utilize EA.hy926 cells, a hybrid cell type that is a fusion of
drug-resistant lung cancer with human umbilical vein cells.209 Briefly, EA.hy926 cells are exposed
to a range of radiation does (0, 2, 4, and 8 Gray (Gy)), seeded in a multi-well plate, incubated for
eight hours, and then observed using HSLCI for 24 hours to measure mass kinetics. This
experiment has been repeated two times.
Interestingly, dose-dependent increases in median population mass were observed in treated
groups. Specifically, while control cells grew and then divided, division in treated populations
was not observed. Instead, treated cells accumulated mass but did not divide, with the 8 Gy
group exhibiting the largest median cell masses at 32 hours, post-dosing. Follow-on studies aim
to reproduce these results while observing cells over a longer time window to detect any cell
divisions in treated groups. We hope to continue this work by comparing responses of cell lines
derived from Caucasian and African American patients in an effort to better understand the
effects of radiation therapy and, potentially, develop markers for the retroactive quantification
of radiation exposure.
6.3.3 PDX Models with HSLCI to Study Drug Resistance
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HSLCI is highly complementary to a powerful emerging clinical research tool: patient-derived
xenografts (PDX). PDX models maintain the genetic and histologic characteristics of the patient
from whom they originate.210–213 Therapeutic compound screening in these models can identify
drugs that are effective in treating tumors from the patients from which they were derived and/or
for patients with a similar genomic profile. One of the best attributes of PDX models is that they
are maintained within an in vivo setting from the time they are isolated from a patient. This feature
conserves cellular heterogeneity by avoiding clonal selection due to 2D culturing on plastic
surfaces. Further, cell-to-cell variability observed within established cell lines has been well
documented, and studies with transgenic models have revealed genomic mechanisms that drive
drug resistance in response to targeted therapeutics.214–216 Pairing HSLCI with PDX models could
enable the rapid identification of patient-specific efficacious chemotherapeutics.
We have tested the HSLCI system with patient-derived melanoma, breast, brain, lung, and
blood cancer cell lines, as well as PDX lines. The platform is unique among biomass
measurement methods in its combination of sampling depth, speed, and compatibility with
both adherent and non-adherent cells, single cells and cell clusters.
An overview of PDX model generation and usage methodologies is shown in Figure 30. Briefly, a
tumor surgically resected from a cancer patient is disaggregated into a single-cell suspension.
The suspension is transplanted into an immunodeficient mouse and allowed to grow. After
sufficient growth, the tumor is removed and transplanted into a second immunodeficient mouse
for tumor expansion. Expanded tumors can then be utilized in studies or cryopreserved for
future use.217
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Figure 30. Overview of PDX model generation and usage. Tumor cells from a cancer patient
are excised, disaggregated, and filtered to yield a single-cell suspension. The suspension is
injected into an immunodeficient mouse, with or without membrane protein augmentation,
for engraftment. Cells are most commonly introduced intravenously or subcutaneously. The
tumor is allowed to expand to a size sufficient for removal and secondary transplantation
into multiple immunodeficient mice. At this stage, the secondary transplant recipients can be
used to multiple ends: 1) biological characterization (i.e. tumorigenesis, metastasis), 2) drug
screening using excised tumor cells, and 3) genetic characterization of tumors via
sequencing. Results from any of these avenues can be used to inform further studies and,
ideally, the personalized selection of therapeutics.

Successful PDX model generation depends upon the optimization of several parameters,
including the choice of an appropriate genetic background of immunodeficient mouse and
selection of transplantation methodology and location. These choices depend both on the type
of cancer being transplanted and the overall research aims. Specifically, establishment of models
from primary tumor samples requires mice with a high degree of immunodeficiency and,
therefore, necessitates the use of mouse strains such as NOD/SCID/IL2rg-/- (NSI), which lack B,
NK, and T cells. Further, these models are now frequently humanized after transplantation via
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the infusion of human hematopoietic stem cells to better mimic the human immune
environment, improving the model’s general relevance. To enhance the likelihood of successful
tumor establishment, transplantation of cells into these mice is frequently augmented with
basement membrane proteins (i.e. Matrigel, Corning, Inc.) and/or fibroblasts and endothelial
cells. Intravenous and subcutaneous (heterotopic) injections are the most common for initial
implantation due to their relative technical simplicity and ease of monitoring, though organspecific (orthotopic) implantation is an option that, theoretically, better mirrors the environment
of human tumors. Once established, PDX models are valuable tools for both basic and preclinical
cancer research. In addition to enabling the study of complex processes like metastasis and
tumorigenesis, they provide a platform for screening drugs and identifying new therapeutic
targets, both in vitro and in vivo.218–220
In collaboration with Dr. Chuck Harrell in the VCU Department of Pathology, we are investigating
drug responses in PDX models of Triple-Negative Breast cancer (TNBC). Briefly, in 2018, an
estimated 266,000 women in the United States will be diagnosed with invasive breast cancer
and ~40,000 will die of the disease.82 The annual death rate due to breast cancer has declined
over the past several decades due to earlier detection and advances in our understanding of
the disease’s molecular subtypes, which govern treatment and predict prognosis. 221,222
However, clinical courses and outcomes for this common malignancy remain variable despite
the use of therapies guided by a combination of clinical assessments that include tumor
subtyping, clinical grading and staging, and the expression of estrogen (ER), progesterone (PR),
or amplified HER2/neu cell surface receptors. 223,224
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Accounting for ~15% of all breast cancers, TNBC is a particularly aggressive form of the
disease that often metastasizes to vital organs, including the brain, bone, liver, and lungs .225–
228 Breast

tumors that are genetically characterized as basal-like tumors (most of which are

TNBC) often metastasize before they are surgically resected.221,222,229 This metastatic
propensity contributes to the poor prognosis associated with this subtype.230,231 Women with
TNBC are limited to receiving chemotherapy and, despite highly toxic therapeutic regimens,
many eventually die from the burden of their disease. 93,94,232,233
Repeated assessments of tumor sensitivity to available therapeutics could improve clinical
outcomes by staying ahead of developing drug resistance in patients with breast and other
cancers. Therefore, the main goal of our current collaboration is to determine whether HSLCI
can predict in vivo PDX drug sensitivity and resistance and, eventually, to assess the ability of the
HSLCI to characterize mechanisms of tumor heterogeneity in PDX breast cancer models. Over
the past four years, Dr. Harrell has developed a set of models and methods to study the growth,
progression, and molecular mechanisms driving drug sensitivity within breast cancer PDX
models. The focus of our current efforts are PDXs that represent the most aggressive breast
cancer subtypes. These include TNBCs WHIM2, WHIM30, HCI01, HCI09, and HCI10. Each of the
PDX models we are investigating has been RNA-Seq expression profiled and analyzed by
immunohistochemistry for ER, PR, and HER2 status. Dr. Harrell has experience growing each PDX
model as mammary tumors and has quantified their growth rates.
Thus far, we have demonstrated a capability to detect cell growth and death responses in cells
freshly isolated from the WHIM2, WHIM30, HCI01, HCI09, HCI11, and PT52 TNBC PDX mouse
models with the HSLCI platform. An example of this drug sensitivity data from two PDX lines is
90

provided in Figure 31, while an example of our ability to resolve drug resistance at the single-cell
level is provided in Figure 32.

Figure 31. Patient-derived xenograft (PDX) lines PT52 and HCI09 sensitivity to Carboplatin. Data
for PT52 (Carboplatin-sensitive) is shown in the upper panel. Data for HCI09 (Carboplatinresistant) is shown in the lower panel. Each set of boxplots summarizes the hourly growth
rates of a population of cells exposed to escalating concentrations of Carboplatin during a
single experimental replicate. Individual dots in the underlying scatter plots represent the
growth rates of single cells. Boxplot notches are indicative of the 95% confidence intervals for
the medians. Median population growth rates from all experimental replicates are plotted
and fit with sigmoid curves. Error bars indicate the 95% confidence intervals for the medians.
Data adapted from experiments conducted with Graeme Murray in the Reed Lab.
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Figure 32. Single-cell example of PT52
Carboplatin response heterogeneity.
HSLCI images of two PT52 cells, each at
T = 0 min. and T = 600 min., exposed to
100 uM Carboplatin. Single-cell growth
tracks of PT52 cells (resistant, red;
sensitive, blue) shown in HSLCI image.
Initial and final growth rates for each
cell are plotted as gray lines.

Importantly, the drug responses measured to-date match those observed in in vivo studies
conducted by Dr. Harrell (i.e. tumors sensitive to drug administered are also sensitive in vitro).
This data establishes the viability of the sample handling techniques we will use to obtain HSLCImeasurable results from surgically resected material, and lays the groundwork for large-scale
studies for quantifying drug resistance and heterogeneity.
6.4 Future Directions
Following the efforts described above, additional studies are planned to expand the scope of
previous experiments and keep pace with emerging trends.
6.4.1 Three-Dimensional Cell Culture
While two-dimensional in vitro culturing remains dominant in cancer and drug development
studies, mounting evidence on the importance of the tumor microenvironment has led to the
emergence of new three-dimensional techniques that aim to better mimic in vivo conditions.234–
236

Specifically, two-dimensional cultures lack stromal cells and features like the extracellular

matrix, have altered rates of drug diffusion, and subject cells to different surface textures than
encountered in the body, all of which can alter behavior and responses to therapeutics. Tumor
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spheroids and organoids are two distinct but similar 3D approaches that have been developed to
address these concerns.237,238
There is currently no single standard protocol for developing these 3D models. Spheroids
typically refer to self-assembled spherical aggregates of cells several hundred microns in
diameter.239 Creating them involves starting with purified tumor cells (though mixed populations
can be used) and using a variety of techniques to encourage them to form such assemblages.
Some methods rely on preventing adhesion to culture vessel surfaces to promote cell clustering,
while others uses a synthetic extracellular matrix called Matrigel (Corning Life Sciences, Inc.) to
foster 3D architectures and separate tumor cells from fibroblast feeder layers.240 Others keep
cells suspended under continuous motion to prevent adhesion; some allow them to sediment to
the bottoms of individual media droplets. Finally, a whole range of micropatterned surfaces have
been created to coax cells into various shapes and structures using microfluidics. Organoids
generally refer to slightly larger, more complex, and more organized clusters of tissue excised
from a mouse or human using enzymatic and mechanical digestion.241 Once excised, these
primary organoids are often similarly cultured in Matrigel or collagen. Spheroids and organoids
can eventually be transferred to traditional multi-well plates for imaging, or cultured in custom
PDMS molds which allow gas and nutrient diffusion and have refractive indices similar to glass.
As 3D culture becomes more common, it will be necessary to demonstrate HSLCI’s compatibility
with spheroids and organoids.242 We have already shown an ability to reliably image cell clumps
and clusters in two-dimensional culture models. Therefore, the biggest challenge will be the
acquisition of data from different focal planes. If we aim to simply study whole clusters,
generating this data requires no modifications to our system because our measurements take
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into account the entire optical path of the light measured, whether it passes through one cell or
ten. However, if we hope to maintain single-cell resolution for correlative fluorescent imaging,
image acquisition approaches similar to those employed by confocal microscopy will be
considered, in addition to the incorporation of additional QPI modalities like DHM or spatial light
interference microscopy (SLIM).243
6.4.2 Large-Scale Patient Studies
A logical extension of our completed and ongoing experiments is the design of larger scale
patient studies. For our work in melanoma, HSLCI dose response testing of primary tumor
samples prior to the administration of therapeutic regimens would enable a comparison of our
assays’ outcomes with actual patient responses. With this material, we could also begin attempts
at comparing 2D and 3D culture methodologies in parallel. In addition, these assays could be
performed for other cancers in which biopsies are straightforward to attain, including breast and
blood cancers. Other groups have demonstrated success in correlating drug-induced in vitro
mass changes with therapeutic efficacy in small numbers of patients.57 If HSLCI is to be adapted
for clinical use, this type of validation will be a mandatory next step.
Regarding our work in T cells, follow-on studies with larger patient cohorts will enable several
lines of inquiry. First, considering the small size of our pilot study, we would hope to reproduce
the trends we observed in our original data and increase the number of control group patients
(autologous transplant recipients). Second, we hope to identify important T cell subsets that
could enhance the resolution of our kinetic signatures. Accomplishing this goal requires both
more patient material and additional resources for requisite analyses. Finally, given the range of
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diseases that can lead to the need for SCT and the broad demographics of those patient
populations, a larger cohort would help us account for any effects these variables might
impart.244
6.5 Conclusion
HSLCI shows promise as a powerful and versatile research tool. We have demonstrated its
compatibility with a wide range of cell types and applications and validated its performance in
two independent laboratories. At present, HSLCI’s large data footprint is its most significant
drawback, both in terms of the cost of data storage and time required for processing. Addressing
this issue is, fortunately, straightforward given the existence of hardware solutions like powerful
graphics processing units (GPUs) that are better suited to image-based tasks and high-capacity
solid-state drives (SSDs) capable of rapidly reading and writing data. In addition, minor software
modifications will streamline data acquisition and analysis, increasing the efficiency of storage
and processing times. These improvements, coupled with our laboratory’s ongoing work and
planned studies, will enable HSLCI to continue contributing to the understanding of mass kinetics
and their importance in biology and medicine.
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Supplementary Figures

Supplementary Figure 1. 24-Well Plate Topography Topography of a typical 24-well glassbottomed plate, displayed in terms of the relative z position (um) of the HSLCI microscope’s
objective. Z-position at any point is indicative of “best focus”zzz as determined by the
platform’s automated focusing feedback loop. The feedback loop detects changes in the
distance between the plate bottom and the microscope objective hundreds of times per
second, adjusting a piezo to which the microscope objective is mounted to maintain best
focus throughout lateral scanning of the sample
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Supplementary
Figure 2. 7-day
proliferation assay.
Live cell counts by
day, normalized to
day 0. All three
melanoma sensitive
and resistance
paired cell lines
were exposed to
increasing doses of
Vemurafenib, or
vehicle (0.1%
DMSO) and media
controls. A
representative
experiment is shown
(n = 3).
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Supplementary Figure 3. Example distributions of single cell growth rates over time. A) M249P
parental line grown in DMEM. B) M249R4 resistant line under treatment with 5𝜇M of
Vemurafenib. C) GFP-M249R4 under treatment with 5𝜇M of Vemurafenib. Hourly growth
rates are estimated by linearly fitting selected single cell data points that were collected
within each hour of the experiment for a span of 24 hours. Single cell tracks were quality
controlled using a upper cutoff of 1.5% standard deviation of residuals in linear regression.
Due to the short time window, there is larger error in the estimation of growth rates than in
data shown in Figures 19-21.
Supplementary Figure 4. Detecting minority
resistant cells in a mixed population. Example
biomass versus growth rate data from a 10:1
M249P (sensitive; blue) : M249R4-GFP (resistant;
red) cell mixture exposed 5μM Vemurafenib for 48
hours. Cell identities are marked by fluorescence
signals.
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Supplementary Tables
Supplementary Table 1. Patient-Derived Melanoma Lines
Cell Line Designation

Molecular Lesions

M229P
M229R5
M238P
M238R1
M249P
M249R4

BRAF V600E
BRAF V600E, PDGFR up-regulation
BRAF V600E
BRAF V600E, PDGFR up-regulation
BRAF V600E
BRAF V600E, N-RAS Q(61)K

Supplementary Table 2. Kinase Inhibitor Dosing Chart
Serum Conc.
(ng/mL)
μM (1x)

Trade

Drug

Chemical

Clinical Dose

Target

Tafinlar

Dabrafenib

GSK2118436

150 mg twice daily

BRAF

1050

2.02

Cotellic

Cobimetinib

GDC-0973 / RG7420

60 mg once daily

MEK1

273

0.51

N/A

Selumetinib

AZD6244 / ARRY-142886 75 mg twice daily

MEK1

1165

2.55

Mekinist Trametinib

GSK1120212

2 mg once daily

MEK1/2

22.2

0.04

N/A

MEK162 / ARRY-162

45 mg twice daily

MEK1/2

257.0

0.58

Binimetinib

Supplementary Table 3. Mast Cell Fluorescence Experiments
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Supplementary Methods
M249R4-GFP cell generation. Third generation lentiviral construct pMD.G (VSV-G envelope) was
used in combination with pMDLg/pRRE (gag/pol elements) and pRSV-REV. Lentivirus was
produced by transient plasmid co-transfection into HEK293T cells. Infections used protamine
sulphate, with mGFP subcloned into the FUGW vector. M249R4 GFP-positive cells were obtained
using a BD FACSAria sorter. GFP expression was determined 4 days after sorting by a BD LSRII flow
cytometer. FACS Diva analysis showed 98.4% of M249R4-GFP cells express mGFP.
Drug Sourcing and Preparation. Imatinib (Cat.# S1026), Dabrafenib (Cat.# S2807), Selumetinib
(Cat.# S1008), Trametinib (Cat.# S2673), Cobimetinib (5mg, Cat.# S8041) and Binimetinib (10mg,
Cat.# S7007) were purchased from Selleck Chemicals (Houston, TX). Imatinib, Vemurafenib,
Dabrafenib, Selumetinib, and Trametinib were supplied at 10mM in DMSO. Cobimetinib and
Binimetinib were supplied as dry powders but suspended in DMSO to a final stock concentration
of 10mM upon receipt.
Kinase Inhibitor 1X Dose Determination: For each inhibitor, a “1X” dose was calculated. Briefly,
clinical doses were obtained from publically-available package inserts or, if none were available,
the median dose administered in clinical trials. Doses were matched to peak serum concentration
values (Cmax (ng/mL)) for each inhibitor as measured in clinical trials in which the doses were
utilized. If multiple Cmax values were available, those values were averaged to yield a single peak
serum concentration value. Using each drugs’ molecular weight, peak serum concentration values
were converted to micromolar (μM) units and designated as “1X”. Unless otherwise noted, clinical
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doses were sourced from package inserts and used to identify Cmax values in studies. References
for Cmax determinations: imatinib

4-6,

dabrafenib

7-8,

Cobimetinib 9, Selumetinib

determined from median of clinical trial doses), Trametinib

14,

and Binimetinib

10-13

(dose

15-16

(dose

determined from median of clinical trial doses).
Cell proliferation assay. Cells in multiple six-well tissue culture plates were incubated overnight at
37oC, 5% CO2. Each six-well plate contained one well with a media control, one well with 0.1%
DMSO vehicle control, and four wells of Vemurafenib at 1 μM, 3 μM, 5 μM, or 10 μM
concentrations. Cells were counted each day for five days following seeding.
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